DEF 14A
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN
PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT
TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT
NO. ____)
Filed by the Registrant [X]
Filed by a Party other than the [_]
Registrant
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] Confidential, for Use of the
Commission Only (as permitted by Rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional
Materials
[_] Soliciting Materials under
Rule 14a-12
BNY Mellon Alcentra Global Credit Income 2024 Target
Term Fund, Inc.
BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc.
BNY Mellon High Yield Strategies Fund
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other
than the Registrant)
Payment of Filing Fee (check the appropriate box):
[X] No fee required.
[_] Fee computed on table below
per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:
(4) Proposed maximum aggregate value of transaction:
(5) Total Fee Paid:
[_] Fee paid previously with
preliminary materials.
| [_] | Check box if any part of the fee is offset as provided by Exchange Act Rule 0- 11(a)(2) and identify the filing for which the offsetting
fee was paid previously. |
Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
BNY MELLON HIGH YIELD
STRATEGIES FUND
BNY Mellon ALCENTRA
GLOBAL CREDIT INCOME 2024 TARGET TERM Fund, INC.
BNY Mellon ALCENTRA
GLOBAL MULTI-STRATEGY CREDIT FUND, INC.
c/o BNY Mellon Investment Adviser, Inc.
240 Greenwich Street
New York, New York 10286
1-800-373-9387
www.im.bnymellon.com
August 26, 2022
Dear Shareholder:
Enclosed are a Notice and
a Joint Proxy Statement concerning a Special Joint Meeting of Shareholders (the "Special Meeting") of BNY Mellon High Yield
Strategies Fund (the "High Yield Strategies Fund"), BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. (the
"Target Term Fund"), and BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. (the "Multi-Strategy Fund") (each,
a "Fund" and collectively, the "Funds"). At the Special Meeting, shareholders of each Fund will be asked to approve
a sub-investment advisory agreement (the "Sub-Advisory Agreement") between the Fund's investment adviser, BNY Mellon Investment
Adviser, Inc. ("BNYM Adviser"), on behalf of the Fund, and Alcentra NY, LLC ("Alcentra NY"), which is currently an
affiliate of BNYM Adviser.
Currently, the High Yield
Strategies Fund's portfolio managers are dual employees of BNYM Adviser and Alcentra NY, and manage the High Yield Strategies Fund as
employees of BNYM Adviser. For the Target Term Fund and Multi-Strategy Fund (together, the "Sub-Advised Funds"), Alcentra NY
has served as each Sub-Advised Fund's sub-adviser since the Fund's inception, pursuant to a sub-investment advisory agreement between
BNYM Adviser and Alcentra NY, with respect to the Sub-Advised Fund (each, a "Current Sub-Advisory Agreement").
Alcentra NY is a subsidiary
of Alcentra Group Holdings, Inc. (together with Alcentra NY, "Alcentra"), which is currently an indirect, wholly-owned subsidiary
of The Bank of New York Mellon Corporation ("BNY Mellon"), the parent company of BNYM Adviser. BNY Mellon has entered into a
definitive agreement with Franklin Resources, Inc., a global investment management organization
operating as Franklin Templeton, pursuant to which Franklin Templeton will, subject to certain regulatory approvals and satisfaction of
other conditions, acquire Alcentra (the "Transaction"). The Transaction is expected to be completed by or before the
first quarter of 2023 (the "Closing Date"), at which time Alcentra NY will become a subsidiary of Franklin Templeton and the
High Yield Strategies Fund's portfolio managers will cease being employees of BNYM Adviser and will be employees of Alcentra NY only.
In addition, as a result of the Transaction, there will be a "change in control" of Alcentra NY, which will effect an assignment
and automatic termination of the Current Sub-Advisory Agreement with respect to each Sub-Advised Fund, pursuant to its terms and the applicable
provisions of the Investment Company Act of 1940, as amended (the "1940 Act").
To enable Alcentra NY to
continue to provide sub-investment advisory services to the Sub-Advised Funds, and for the High Yield Strategies Fund's portfolio managers
to provide day-to-day management of the Fund's investments as employees of Alcentra NY, in each case as of the Closing Date, when Alcentra
NY will become a subsidiary of Franklin Templeton, the Board of each Fund, including a majority of the Board members who are not "interested
persons" (as that term is defined in the 1940 Act) of the Fund ("Independent Board Members"), approved the Sub-Advisory
Agreement, which requires approval by a majority of the relevant Fund's outstanding voting securities (as defined in the 1940 Act) before
it can go into effect. Therefore, the Board has called the Special Meeting to seek shareholder approval of the Sub-
Advisory Agreement for each Fund in order to
ensure that Alcentra NY can provide uninterrupted service as sub-adviser to the Sub-Advised Funds and provide continuity of portfolio
management for the High Yield Strategies Fund after the Closing Date.
There will be no increase
in the advisory fee payable by a Fund to BNYM Adviser as a consequence
of the Transaction. With respect to the High Yield Strategies Fund, the sub-advisory fee payable to Alcentra NY under the Sub-Advisory
Agreement will be payable by BNYM Adviser and not the Fund. With respect to each of the Target Term Fund and Multi-Strategy Fund, the
sub-advisory fee payable by BNYM Adviser to Alcentra NY under the Sub-Advisory Agreement will be the same as that payable to Alcentra
NY under the respective Current Sub-Advisory Agreement. As to each Sub-Advised Fund, the Sub-Advisory Agreement is substantially similar
in material respects to the Current Sub-Advisory Agreement. In addition, as to each Fund, the Fund's investment objective, strategies
and policies will not change in connection with the implementation of the Sub-Advisory Agreement.
After careful review, as
to each Fund, the Board members present at an in-person meeting, including a majority of the Independent Board Members, unanimously approved
the Sub-Advisory Agreement, subject to shareholder approval. The Board recommends that you read the enclosed materials carefully and then
vote to approve the Sub-Advisory Agreement for your Fund.
Your vote is extremely
important, no matter how large or small your Fund holdings. By voting promptly, you can help avoid follow-up letters and calls. If you
own shares of more than one of the Funds on the record date for the meeting, please note that each Fund has a separate proxy card.
You should vote one for each Fund in which you own shares.
To vote, you may use
any of the following methods:
| · | By Mail. Please complete, date and sign the enclosed proxy card and mail it in the enclosed postage-paid
envelope. |
| · | Over the Internet. Have your proxy card available. Go to the website listed on the proxy card.
Enter your control number from your proxy card. Follow the instructions on the website. |
| · | By Telephone. Have your proxy card available. Call the toll-free number listed on the proxy card.
Enter your control number from your proxy card. Follow the recorded instructions. |
| · | At the Meeting. Any shareholder who attends the meeting virtually may vote over the Internet during
the meeting. |
Due to the public health
and safety concerns regarding COVID-19, and to support the health and well-being of the Funds' shareholders, officers and others, the
meeting will be conducted over the Internet in a virtual meeting format only. However, we intend
to monitor the recommendations of public health officials and governmental restrictions, and if we decide it is appropriate to hold the
meeting in person, we will make an announcement in the manner discussed in the proxy materials.
We encourage you to vote
over the Internet or by telephone using the number that appears on your proxy card. If you later decide to attend the meeting virtually,
you may revoke your proxy and vote your shares over the Internet during the meeting. Whichever voting method you choose, please take the
time to read the full text of the Joint Proxy Statement before you vote. If you have any questions before you vote, please call the Funds'
proxy solicitor, AST Fund Solutions, LLC, at (866) 796-7181.
Thank you for your response
and for your continued investment with the Fund(s).
Sincerely,
David DiPetrillo
President
BNY Mellon Family of Funds
BNY MELLON HIGH YIELD
STRATEGIES FUND
BNY Mellon ALCENTRA
GLOBAL CREDIT INCOME 2024 TARGET TERM Fund, INC.
BNY Mellon ALCENTRA
GLOBAL MULTI-STRATEGY CREDIT FUND, INC.
______________________________________________
Notice of Special Joint Meeting of Shareholders
To Be Held on October 13, 2022
______________________________________________
To the Shareholders:
A Special Joint Meeting
of Shareholders (the "Meeting") of each fund listed above (each, a "Fund" and collectively, the "Funds")
will be held over the Internet in a virtual meeting format only on Thursday, October 13, 2022 at 10:00 a.m., Eastern Time, for the following
purposes with respect to each Fund:
1. |
To approve a sub-investment advisory agreement between BNY Mellon Investment Adviser, Inc., on behalf of the Fund, and Alcentra NY, LLC; and |
|
|
2. |
To transact such other business as may properly come before the Meeting, or any adjournment(s) thereof. |
Due
to the public health and safety concerns regarding COVID-19, and to support the health and well-being of the Funds' shareholders,
officers and others, the Meeting will be held in a virtual meeting format only. You will not be able to attend the Meeting in person,
but you may participate over the Internet as described below. However, we intend to monitor the
recommendations of public health officials and governmental restrictions, and if we decide it is appropriate to hold the Meeting in person,
we will make an announcement in the manner noted below.
Shareholders
of record at the close of business on August 16, 2022 will be entitled to receive notice of and to vote at the Meeting.
To
participate in the Meeting, you must request the Meeting credentials by emailing attendameeting@astfinancial.com. Please include your
full name, address, your control number found on your enclosed proxy card, your intent to attend the virtual Meeting and "[Name of
Fund]" in the subject line. The Meeting will begin promptly at 10:00 a.m., Eastern Time, on Thursday, October 13, 2022. If you hold
your shares through an intermediary, such as a bank or broker, you must register in advance of the Meeting. To register, you must submit
proof of your proxy power (legal proxy provided by your intermediary) reflecting your Fund holdings along with your name and email address
to attendameeting@astfinancial.com. You may also forward proof of ownership from your intermediary or attach an image of your legal proxy
to attendameeting@astfinancial.com. Requests for registration should be received no later than 12:00 p.m., Eastern Time, on Monday, October
10, 2022. You will receive a confirmation email from attendameeting@astfinancial.com of your registration and control number that will
allow you to vote at the Meeting.
PLEASE
NOTE: If it is determined that the Meeting will be held in person, instead of virtually, an announcement of the change will be provided
by means of a press release, which will be posted on our website https://im.bnymellon.com/us/en/individual/resources/proxy-materials.jsp.
We encourage you to check the website prior to the meeting. An announcement of any change will also be filed with the Securities and Exchange
Commission via its EDGAR system.
By
Order of the Boards,
James Bitetto
Secretary
New
York, New York
August 26, 2022 |
WE NEED YOUR PROXY VOTE.
A SHAREHOLDER MAY THINK HIS OR HER VOTE IS
NOT IMPORTANT, BUT IT IS VITAL. BY LAW, THE MEETING OF SHAREHOLDERS OF A FUND WILL HAVE TO BE ADJOURNED WITHOUT CONDUCTING ANY
BUSINESS IF LESS THAN A QUORUM OF FUND SHARES ELIGIBLE TO VOTE IS REPRESENTED. IN THAT EVENT, THE AFFECTED FUND WOULD CONTINUE TO SOLICIT
VOTES IN AN ATTEMPT TO ACHIEVE A QUORUM. CLEARLY, YOUR VOTE COULD BE CRITICAL TO ENABLE YOUR FUND TO HOLD THE MEETING AS SCHEDULED, SO
PLEASE RETURN YOUR PROXY CARD(S) OR OTHERWISE VOTE PROMPTLY. YOU AND ALL OTHER SHAREHOLDERS WILL BENEFIT FROM YOUR COOPERATION. |
BNY MELLON HIGH YIELD
STRATEGIES FUND
BNY Mellon ALCENTRA
GLOBAL CREDIT INCOME 2024 TARGET TERM Fund, INC.
BNY Mellon ALCENTRA
GLOBAL MULTI-STRATEGY CREDIT FUND, INC.
JOINT PROXY
STATEMENT
Special Joint Meeting of Shareholders
to be held on Thursday, October 13, 2022
This Joint Proxy Statement
is furnished in connection with a solicitation of proxies by the Board of Trustees/Directors (the "Board") of each of BNY Mellon
High Yield Strategies Fund (the "High Yield Strategies Fund"), BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund,
Inc. (the "Target Term Fund") and BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. (the "Multi-Strategy Fund")
(each, a "Fund" and, collectively, the "Funds") to be used at the Special Joint Meeting of Shareholders (the "Meeting")
of each Fund to be held over the Internet in a virtual meeting format only on Thursday, October 13, 2022 at 10:00 a.m., Eastern Time,
and at any and all adjournments thereof, for the purposes set forth in the accompanying Notice of Special Joint Meeting of Shareholders.
Shareholders of record
as of the close of business on August 16, 2022 are entitled to receive notice of and to vote at the Meeting. Shareholders are entitled
to one vote for each Fund share held and fractional votes for each fractional Fund share held. Shareholders can vote only on matters affecting
the Fund(s) in which they hold shares. Shareholders will not be able to attend the Meeting in person, but may participate over the Internet
as described in the Notice of Special Joint Meeting of Shareholders.
Fund
shares represented by executed and unrevoked proxies will be voted in accordance with the specifications made thereon. Unmarked but properly
signed and dated proxy cards will be voted "FOR" the proposal. If the enclosed proxy card is executed and returned, or if you
have voted by telephone or over the Internet, your vote nevertheless may be revoked after it is received
by sending a written notice of revocation to the proxy tabulator at the address listed on the proxy card or by mailing a duly executed
proxy bearing a later date; you may also change your vote by mailing a duly executed proxy bearing a later date, by calling the toll-free
telephone number listed under "To vote by Telephone" on the proxy card or over the Internet
by going to the website listed on the proxy card and following the instructions on the website. To be effective, such revocation or vote
change must be received before your prior proxy is exercised at the Meeting. If you hold shares through a bank or other intermediary,
please consult your bank or intermediary regarding your ability to revoke voting instructions after such instructions have been provided.
In addition, any shareholder who attends the Meeting virtually may vote over the Internet during
the Meeting, thereby canceling any proxy previously given.
Information as to the number
of shares outstanding and share ownership for each Fund is set forth on Schedule 1 to this Joint Proxy Statement.
The approximate
mailing date of this Joint Proxy Statement and the accompanying proxy card is September 9, 2022. Please note that only one
copy of this Joint Proxy Statement will be mailed to those addresses shared by two or more accounts. If you wish to revoke this
arrangement and receive individual copies, you may do so at any time by writing to the address or calling the phone number set forth
below. Your Fund will begin sending you individual copies promptly after receiving your request.
The principal executive
offices of each Fund are located at 240 Greenwich Street, New York, New York 10286. Copies of each Fund's most recent Annual Report
to Shareholders and, if applicable, Semi-Annual Report to Shareholders are available upon request, without charge, by writing to the
Fund at 144 Glenn Curtiss Boulevard,
Uniondale, New York 11556-0144, visiting www.im.bnymellon.com or calling toll-free 1-800-373-9387.
Important
Notice Regarding the Availability of Proxy Materials for the Special Joint Meeting of Shareholders to be Held on October
13, 2022:
The Letter to Shareholders,
Notice of Special Joint Meeting of Shareholders and Joint Proxy Statement are available at https://im.bnymellon.com/us/en/individual/resources/proxy-materials.jsp. |
PROPOSAl: approval
of a sub-investment advisory agreemEnt
Introduction
Currently, the High Yield
Strategies Fund's portfolio managers are dual employees of the High Yield Strategies Fund's investment adviser, BNY Mellon Investment
Adviser, Inc. ("BNYM Adviser"), and Alcentra NY, LLC ("Alcentra NY"), which is currently an affiliate of BNYM Adviser,
and manage the High Yield Strategies Fund as employees of BNYM Adviser. Alcentra NY currently serves as the sub-adviser to the Target
Term Fund and the Multi-Strategy Fund (together, the "Sub-Advised Funds"), pursuant to a current sub-investment advisory agreement
between BNYM Adviser and Alcentra NY, with respect to each Sub-Advised Fund (each, a "Current Sub-Advisory Agreement").
Alcentra NY is a subsidiary
of Alcentra Group Holdings, Inc. (together with Alcentra NY, "Alcentra"), which is currently an indirect, wholly-owned subsidiary
of The Bank of New York Mellon Corporation ("BNY Mellon"), the parent company of BNYM Adviser. In May 2022, BNY Mellon entered
into a definitive agreement with Franklin Resources, Inc., a global investment management organization
operating as Franklin Templeton, pursuant to which Franklin Templeton will, subject to certain regulatory approvals and satisfaction of
other conditions, acquire Alcentra (the "Transaction"). The Transaction is expected to be completed by or before the
first quarter of 2023 (the "Closing Date"), at which time Alcentra NY will become a subsidiary of Franklin Templeton and the
High Yield Strategies Fund's portfolio managers will cease being employees of BNYM Adviser and will be employees of Alcentra NY only.
In addition, as a result of the Transaction, there will be a "change in control" of Alcentra NY, which will effect an assignment
and automatic termination of the Current Sub-Advisory Agreement with respect to each Sub-Advised Fund, pursuant to its terms and the applicable
provisions of the Investment Company Act of 1940, as amended (the "1940 Act").
To enable Alcentra NY to
continue to provide sub-investment advisory services to the Sub-Advised Funds, and the High Yield Strategies Fund's portfolio managers
to provide day-to-day management of the Fund's investments as employees of Alcentra NY, in each case as of the Closing Date, when Alcentra
NY will become a subsidiary of Franklin Templeton, BNYM Adviser recommended and the relevant Fund's Board, including a majority of the
Board members who are not "interested persons" (as that term is defined in the 1940 Act) of the Fund ("Independent Board
Members"), approved a sub-investment advisory agreement (the "Sub-Advisory Agreement") between BNYM Adviser, with respect
to each Fund, and Alcentra NY. Under the 1940 Act, the Sub-Advisory Agreement requires approval by a majority of the relevant Fund's outstanding
voting securities (as defined in the 1940 Act) before it can go into effect. Therefore, the Board has called the Meeting to seek shareholder
approval of the Sub-Advisory Agreement in order to ensure that Alcentra NY can provide uninterrupted service as sub-adviser to the Sub-Advised
Funds and provide continuity of portfolio management for the High Yield Strategies Fund after the Closing Date.
There will be no increase
in the advisory fee payable by a Fund to BNYM Adviser as a consequence
of the Transaction. With respect to the High Yield Strategies Fund, the sub-advisory fee payable to Alcentra NY under the Sub-Advisory
Agreement will be payable by BNYM Adviser and not the Fund. With respect to each of the Target Term Fund and Multi-Strategy Fund, the
sub-advisory fee payable by BNYM Adviser to Alcentra NY under the Sub-Advisory Agreement will be the same as that payable to Alcentra
NY under the respective Current Sub-Advisory Agreement. As to each Sub-Advised Fund, the Sub-Advisory Agreement is substantially similar
in material respects to the Current Sub-Advisory Agreement. In addition, as to each Fund, the Fund's investment objective, strategies
and policies will not change in connection with the implementation of the Sub-Advisory Agreement. As to each Fund, BNYM Adviser and Alcentra
NY have represented to the Board that there would be no diminution in the nature, extent or quality of the services provided to the Fund
in connection with the
implementation of the Sub-Advisory Agreement.
If approved by shareholders at the Meeting, the Sub-Advisory Agreement will go into effect on the Closing Date.
The Transaction is not
contingent on shareholder approval of the Sub-Advisory Agreement. If the Transaction is effected before shareholder approval of the Sub-Advisory
Agreement for a Fund is obtained, each Fund's Board has approved an interim sub-investment advisory agreement (the "Interim Sub-Advisory
Agreement") between BNYM Adviser, on behalf of the Fund, and Alcentra NY, which would take effect on the Closing Date, and the Fund
would continue to solicit shareholder approval of the Sub-Advisory Agreement while the Interim Sub-Advisory Agreement is in place. If
the Interim Sub-Advisory Agreement goes into effect for a Fund, it would expire upon the earlier of 150 days after the Closing Date of
the Transaction or upon shareholder approval and effectiveness of the Sub-Advisory Agreement.
If shareholders of a Fund
do not approve the Sub-Advisory Agreement for their Fund, Alcentra NY would no longer serve as that Fund's sub-adviser pursuant to the
Current Sub-Advisory Agreement, in the case of a Sub-Advised Fund, or provide portfolio management services to the High Yield Strategies
Fund, as applicable, and the Board would take such actions as it deems to be in the best interests of the Fund, which may include resubmitting
the Sub-Advisory Agreement to shareholders for approval or making other sub-advisory or portfolio management arrangements for the Fund.
Information About BNYM
Adviser, Alcentra and Franklin Templeton
BNYM Adviser
BNY Mellon Investment Adviser,
Inc., located at 240 Greenwich Street, New York, New York 10286, serves as investment adviser to each Fund, subject to the supervision
of the Board. Founded in 1947, BNYM Adviser manages approximately $305 billion in 117 mutual fund portfolios as of June 30, 2022. BNYM
Adviser is the primary mutual fund business of The Bank of New York Mellon Corporation ("BNY Mellon"), a global investments
company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. Whether providing
financial services for institutions, corporations or individual investors, BNY Mellon delivers informed investment management and investment
services in 35 countries. BNY Mellon is a leading investment management and investment services company, uniquely focused to help clients
manage and move their financial assets in the rapidly changing global marketplace. BNY Mellon has $43 trillion in assets under custody
and administration and $1.9 trillion in assets under management. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation.
BNY Mellon Investment Management is one of the world's leading investment management organizations, and one of the top U.S. wealth managers,
encompassing BNY Mellon's affiliated investment management firms, wealth management services and global distribution companies. Additional
information is available at www.bnymellon.com.
BNYM Adviser provides management
services to the Funds pursuant to separate agreements (each, a "Management Agreement") as follows: (i) an investment management
and administration agreement between the High Yield Strategies Fund and BNYM Adviser, dated April 22, 1998, amended as of June 3, 2019;
(ii) a management agreement between the Target Term Fund and BNYM Adviser, dated August 31, 2017, amended as of June 3, 2019; and (iii)
a management agreement between the Multi-Strategy Fund and BNYM Adviser, dated May 15, 2019, amended as of June 3, 2019.
Under the Management Agreement
for the High Yield Strategies Fund, BNYM Adviser provides or oversees the provision of all investment advisory and portfolio management
services to the Fund. The Management Agreement provides that, subject to the Board's supervision, BNYM Adviser manages the investment
and reinvestment of the assets of the High Yield Strategies Fund and provides a continuous investment program for the Fund, consistent
with the High Yield Strategies Fund's investment objective,
policies and limitations. Subject to market
conditions, the High Yield Strategies Fund uses leverage as part of its investment management policies by borrowing money from banks in
an amount up to 33-1/3% of the value of its total assets (including the amount borrowed). Under the Management Agreement, BNYM Adviser
also provides a variety of administrative services to the High Yield Strategies Fund, including internal fund accounting and internal
legal services, oversight of the provision to the Fund of custody and transfer agency services, and generally assisting in all aspects
of the High Yield Strategies Fund's operations. In consideration of services rendered pursuant to the Management Agreement, the High Yield
Strategies Fund has agreed to pay BNYM Adviser a monthly fee at the annual rate of .75% of the value of the Fund's average weekly total
assets minus the sum of accrued liabilities (other than the aggregate indebtedness constituting financial leverage). For the High
Yield Strategies Fund's fiscal year ended March 31, 2022, the Fund paid BNYM Adviser $2,496,367,
pursuant to the Management Agreement.
Under the respective Management
Agreement for the Target Term Fund and the Multi-Strategy Fund, BNYM Adviser furnishes a continuous investment program for the Target
Term Fund's and the Multi-Strategy Fund's portfolio and generally manages each Sub-Advised Fund's investments in accordance with the stated
policies of the Fund. The Management Agreements provide that, subject to the respective Board's general supervision, BNYM Adviser is responsible
for the overall management of the Target Term Fund's and the Multi-Strategy Fund's portfolio and for the supervision and ongoing monitoring
of Alcentra NY. Each of the Target Term Fund and the Multi-Strategy Fund may employ leverage to enhance its potential for achieving its
investment objectives. The Target Term Fund and the Multi-Strategy Fund currently intend to utilize leverage in an amount equal to 30%
of their respective total assets, but may borrow up to the limits imposed by the 1940 Act (i.e., 33-1/3% of their respective total assets),
principally through loans from certain financial institutions and/or the issuance of debt securities (collectively, "Borrowings").
In addition, the Target Term Fund and the Multi-Strategy Fund may obtain effective leverage through portfolio transactions, which, in
the case of the Target Term Fund, will be treated as the issuance of debt securities and will be subject to the 33-1/3% limitation on
Borrowings under the 1940 Act. BNYM Adviser also maintains office facilities on behalf of the Sub-Advised Funds, and furnishes statistical
and research data, clerical help, accounting, data processing, bookkeeping and internal auditing and certain other required services to
the Sub-Advised Funds. BNYM Adviser also performs certain other administrative services for each Sub-Advised Fund. In consideration of
services rendered pursuant to the respective Management Agreement, the Target Term Fund and the Multi-Strategy Fund have agreed to pay
BNYM Adviser based on the value of the respective Fund's "Managed Assets," which is defined as the Fund's total assets, including
any assets attributable to leverage (i.e., Borrowings, preferred stock or other similar preference securities ("Preferred Shares"),
or the use of derivative instruments that have the economic effect of leverage), minus the Fund's accrued liabilities, other than any
liabilities or obligations attributable to leverage obtained through (i) indebtedness of any type (including, without limitation, Borrowings),
(ii) the issuance of Preferred Shares, and/or (iii) any other means, all as determined in accordance with generally accepted accounting
principles. The Target Term Fund pays BNYM Adviser a monthly fee at the annual rate of .85% based on the average daily value of the Fund's
Managed Assets, while the Multi-Strategy Fund pays BNYM Adviser a quarterly fee at the annual rate of 1.25% based on the value of the
Fund's Managed Assets calculated each quarter. For the Target Term Fund's fiscal year ended August 31, 2021, the Fund paid BNYM Adviser
$1,636,480, pursuant to the Management Agreement. For the Multi-Strategy Fund's fiscal year
ended March 31, 2022, the Fund paid BNYM Adviser $4,207,955, pursuant to the Management Agreement.
Each Management Agreement
was last approved by the Board for a one-year continuance at a meeting held on March 2-3, 2022 (the "15(c) Meeting"), and by
the respective Fund's initial shareholder on April 23, 1998, September 22, 2017 and June 10, 2019, with respect to the High Yield Strategies
Fund, Target Term Fund and Multi-Strategy Fund, respectively, in connection with each Fund's commencement of operations. A discussion
regarding the basis for the Board's approval of the continuance of the Management Agreement is available in the High Yield Strategies
Fund's and Multi-Strategy Fund's
respective Annual Report for the fiscal year
ended March 31, 2022, and in the Target Term Fund's Annual Report for the fiscal year ended August 31, 2021.
Alcentra
Alcentra Group Holdings,
Inc. is currently a subsidiary of BNY Mellon and is headquartered in London, with offices in New York and Boston. Alcentra was founded
in 2002 and managed more than $38 billion in assets as of April 30, 2022 (including
accounts managed by Alcentra NY, Alcentra Limited, and assets managed by Alcentra personnel for affiliates under dual employee arrangements).
Alcentra's investment strategies include senior loans, high yield bonds, private credit, structured credit, special situations, and multi-strategy
credit. It is currently contemplated that most of Alcentra's employees will remain with Alcentra upon completion of the Transaction.
Alcentra NY is a subsidiary
of Alcentra Group Holdings and its principal office is located at 200 Park Avenue, New York, New York 10166. Alcentra NY provides investment
advisory services focusing on sub-investment grade debt. Alcentra is one of the largest global institutional managers of below investment
grade credit.
Alcentra NY does not currently
serve as investment adviser or sub-adviser to any other registered investment companies which have a similar investment objective and
similar investment management policies as the Funds.
The names and principal
occupations of the principal executive officers of Alcentra NY are: Jonathan DeSimone, Chief Executive Officer; Joseph Cantwell, Chief
Investment Officer – Liquid Credit; Christopher Mulshine, Head of U.S. Distribution; Vinay Patel, Head of Finance; and Steven Levinson,
Chief Compliance Officer. Messrs. DeSimone, Cantwell, Mulshine and Patel are members of Alcentra NY's Executive Committee responsible
for the day-to-day management and oversight of the operations of the firm. The address of each principal executive officer listed above,
as it relates to the person's position with Alcentra NY, is 200 Park Avenue, 7th Floor, New York, New York 10166.
The Current Sub-Advisory
Agreement for each Sub-Advised Fund was last approved by the Board for a one-year continuance at the 15(c) Meeting, and by the respective
Fund's initial shareholder on September 22, 2017 and June 10, 2019, with respect to the Target Term Fund and Multi-Strategy Fund, respectively,
in connection with each such Fund's commencement of operations. A discussion regarding the basis for the Board's approval of the continuance
of the Current Sub-Advisory Agreement is available in the Multi-Strategy Fund's Annual Report for the fiscal year ended March 31, 2022,
and in the Target Term Fund's Annual Report for the fiscal year ended August 31, 2021.
Franklin
Templeton
Franklin
Resources, Inc., whose principal executive offices are at One Franklin Parkway, San Mateo, California 94403, is a global investment management
organization operating, together with its subsidiaries, as Franklin Templeton. Franklin Templeton's mission is to help clients
achieve better outcomes through investment management expertise, wealth management and technology solutions. Through
specialized teams, Franklin Templeton has expertise across all asset classes, including equity, fixed income, alternatives and custom
multi-asset solutions. Franklin Templeton has more than 1,300 investment professionals, who are supported by Franklin Templeton's
integrated, worldwide team of risk management professionals and global trading desk network, and
has employees in over 30 countries. Franklin Templeton has 75 years of investment experience and approximately $1.4 trillion in
assets under management as of July 31, 2022.
As a result of the Transaction
and on the Closing Date, Alcentra will become a subsidiary of Franklin Templeton and will no longer
be an affiliate of BNYM Adviser. Franklin Templeton has stated that the Transaction will continue to strengthen the breadth and scale
of Franklin Templeton's alternative asset strategies and is expected to bring firm-wide alternative assets under management to approximately
$260 billion after the Transaction closes. Franklin Templeton has further stated that Alcentra NY is highly complementary to its existing
U.S. capabilities.
None of the Board members
has, or has had, any material interest in, or a material interest in a material transaction or proposed transaction with Franklin Templeton
since the beginning of a Fund's most recently completed fiscal year.
Information About the Funds'
Primary Portfolio Managers
Messrs. Barris and Cronk
currently serve as primary portfolio managers of each Fund and are expected to continue to serve in such capacity after the Closing Date.
Existing management of Alcentra currently expects that Brandon Chao will be appointed as an additional primary portfolio manager of the
Target Term Fund and Multi-Strategy Fund prior to the Closing Date.
Messrs.
Barris and Cronk have been the High Yield Strategies Fund's
primary portfolio managers since July 2007 and July 2012, respectively. Messrs. Barris and Cronk
are jointly and primarily responsible for managing the High Yield Strategies Fund's portfolio in their capacity as employees of
BNYM Adviser. In choosing securities, the High Yield Strategies Fund's
portfolio managers seek to capture the higher yields offered by junk bonds, while managing credit
risk and the volatility caused by interest rate movements.
Messrs.
Barris and Cronk, together with Hiram Hamilton, currently are the Target Term Fund's
primary portfolio managers. Messrs. Barris and Cronk have held such positions since the Fund commenced
operations in October 2017, and Mr. Hamilton has held such position since February 2018. Messrs. Barris, Cronk and Hamilton are jointly
and primarily responsible for managing the Target Term Fund's portfolio pursuant to the Current
Sub-Advisory Agreement for the Fund. The Target Term Fund's portfolio managers construct
the Target Term Fund's investment portfolio by allocating the Fund's assets to credit instruments
and related investments in the following strategies: (i) Senior Secured Loans and Other Loans; (ii) Corporate Debt; (iii) Special Situations;
and (iv) Structured Credit.
Messrs.
Barris and Cronk, together with Jonathan DeSimone, Mr. Hamilton and Suhail Shaikh,
currently are the Multi-Strategy Fund's primary portfolio managers. Messrs. Barris, Cronk,
Hamilton and Shaikh have held such positions
since the Fund commenced operations in August 2019, and Mr. DeSimone has held such position since January 2021. Messrs. Barris, Cronk,
DeSimone, Hamilton and Shaikh are jointly and primarily responsible for managing the Multi-Strategy
Fund's portfolio pursuant to the Current Sub-Advisory Agreement for the Fund. The Multi-Strategy
Fund's portfolio managers construct the Multi-Strategy Fund's investment
portfolio by allocating the Fund's assets to credit instruments and related investments in
the following strategies: (i) Senior Secured Loans; (ii) Direct Lending and Subordinated Loans; (iii) Special Situations; (iv) Structured
Credit; and (v) Corporate Debt.
Mr. Barris joined Alcentra
in January 2013 as part of the combination of Alcentra with Standish Mellon Asset Management Company LLC's ("Standish") high
yield business, and is the Acting Chief Investment Officer of Liquid Credit at Alcentra. He is responsible for managing all U.S. and global
high yield portfolios, and has extensive experience managing a broad range of high yield bond strategies for both institutional and retail
funds. Mr. Barris also is responsible for managing Alcentra's multi-asset credit portfolios, including U.S. and European bonds and loans.
He has considerable experience in credit analysis with over 25 years of investment experience. Mr. Barris joined Standish, formerly an
affiliate of BNYM Adviser and Alcentra, in 2005 as a Senior Credit Analyst, and elevated to Director and Senior Portfolio
Manager for U.S. and global high yield
investments. Mr. Barris joined Standish from State Street Research & Management where he was as a high yield research analyst.
Prior to that, he worked for Credit Suisse First Boston (Donaldson, Lufkin & Jenrette) in the leveraged finance group. Mr.
Barris has been employed by BNYM Adviser since July 2007. Mr. Barris has an M.B.A. from Columbia Business School and a B.A.
from Hamilton College.
Mr. Cronk joined Alcentra
in January 2013 as part of the combination of Alcentra with Standish's high yield business, and is a Managing
Director and Senior Portfolio Manager and a member of the U.S. Liquid Credit Investment Committee at Alcentra. Mr. Cronk joined
Standish in 2011 from Columbia Management, where he worked for 11 years as a high yield analyst and portfolio manager. Prior to that,
he worked as a high yield investment associate at Putnam Investments. Mr. Cronk has been employed
by BNYM Adviser since July 2012. Mr. Cronk has a B.S. in Business Administration from Creighton University, holds the Chartered
Financial Analyst (CFA®) designation, and is a member of the Boston Security Analysts Society.
Mr.
Chao joined Alcentra in March 2017 and is a Managing Director and Senior Portfolio Manager and a member of the Structured Credit team.
He is responsible for analyzing investments in structured products across Alcentra's funds. Mr. Chao joined Alcentra from Omega Advisors,
where he worked for five years as a senior analyst covering structured products with a focus on CLO equity and mezzanine investing and
opportunistic corporate credit. Prior to that, he worked at King Street Capital Management, investing in corporate structured products,
high yield, and distressed credit, and at Credit Suisse, performing leveraged finance research. Mr. Chao has a B.S. in Finance from the
Massachusetts Institute of Technology and holds the Chartered Financial Analyst (CFA®) designation.
Mr. DeSimone joined Alcentra
in September 2020 as Chief Executive Officer. He serves as Chair of the firm's Executive Management Committee and interim Chief Investment
Officer of Private Credit. Mr. DeSimone joined Alcentra from Bain Capital Credit (formerly, Sankaty Advisors), where he served as Chief
Investment Officer for Liquid Credit and a member of the Credit Committee. Prior to that, Mr. DeSimone worked at Bain & Company, supporting
a variety of clients in the consumer, industrial and private equity sectors. Mr. DeSimone has an M.B.A. from the Amos Tuck School at Dartmouth
College and a B.A. in Economics from Georgetown University.
Mr. Hamilton joined Alcentra
in March 2008 and is a Managing Director and Co-Head of the Structured Credit business and oversees investments in structured products
across Alcentra's funds. Mr. Hamilton joined Alcentra from Morgan Stanley, where he was an Executive Director and Head of the Collateralized
Debt Obligations Group. Prior to that, Mr. Hamilton was an Analyst at Prudential Securities in the Asset Backed Securities Group. Mr.
Hamilton has a B.A. in Philosophy and Neuroscience from Bowdoin College.
Mr. Shaikh joined Alcentra
in May 2018 and serves as Managing Director, Head of U.S. Private Credit and Vice Chair of the Private Credit Investment Committee. He
also served as the Chief Executive Officer and a Board Member of Alcentra Capital Corporation, a publicly listed business development
company formerly managed by Alcentra. Mr. Shaikh joined Alcentra from SLR Capital Partners LLC (formerly, Solar Capital Partners LLC),
where he was a partner and senior investment professional. Prior to that, Mr. Shaikh was in investment banking serving as a leveraged
finance specialist and financial sponsor banker, at Bank of America Merrill Lynch, CIBC World Market, and JPMorgan & Co. Mr. Shaikh
has an M.B.A. from The Wharton School of Business with a concentration in Finance and an A.B. in Computer Science and Economics from Middlebury
College.
Sub-Advisory Agreements
The following discussion is a description
of the material terms of the Sub-Advisory Agreement. The form of the Sub-Advisory Agreement is attached as Exhibit A to this Proxy Statement.
As to each Fund, the Sub-Advisory
Agreement was approved by the Board, including a majority of the Independent Board Members, at an in-person Board meeting held on August
4, 2022 (the "August Meeting"), which was called, among other reasons, for the purpose of approving the Sub-Advisory Agreement.
If approved by Fund shareholders, the Sub-Advisory Agreement will become effective on the Closing Date and will continue until April 4,
2023, and thereafter is subject to annual approval by the Board, including a majority of the Independent Board Members. As to each of
the Target Term Fund and Multi-Strategy Fund, the Sub-Advisory Agreement is substantially similar in material respects to the Current
Sub-Advisory Agreement, with certain differences as described below.
As is the case under the
Current Sub-Advisory Agreement with respect to each Sub-Advised Fund, pursuant to the Sub-Advisory Agreement for each Fund, Alcentra NY,
subject to the supervision and approval of BNYM Adviser and the Board, will provide the day-to-day management of the Fund's investments.
Alcentra NY, among other duties, will obtain and provide investment research and supervise the Fund's
investments and will conduct a continuous program of investment, evaluation and, if appropriate, sale and reinvestment of the Fund's
assets, including the placing of portfolio transactions for execution with either the issuer directly or with any broker or dealer, foreign
currency dealer, futures commission merchant, counterparty or other entities. Alcentra NY also will perform certain other administrative
and compliance-related functions in connection with the management of the Fund's assets.
As is the case under the
Current Sub-Advisory Agreement with respect to each Sub-Advised Fund, as to each Fund, the Sub-Advisory Agreement provides that Alcentra
NY shall exercise its best judgment in rendering the services to be provided pursuant to the Sub-Advisory Agreement. As to each Fund,
the Sub-Advisory Agreement provides, as does the Current Sub-Advisory Agreement for the Sub-Advised Funds, that Alcentra NY will not be
liable for any error of judgment or mistake of law or for any loss suffered by the Fund or BNYM Adviser, except by reason of willful misfeasance,
bad faith or gross negligence in the performance of Alcentra NY's duties, or by reason of Alcentra NY's reckless disregard of its obligations
and duties, under the Sub-Advisory Agreement. In addition, as to each Fund, the Sub-Advisory Agreement provides that Alcentra NY indemnify
and hold harmless the Fund and BNYM Adviser and their affiliates and control persons and that BNYM Adviser indemnify and hold harmless
Alcentra NY and its affiliates and control persons, against certain losses, claims, damages, liabilities or litigation. Although the Current
Sub-Advisory Agreements for the Sub-Advised Funds contain indemnification provisions, these provisions have been expanded upon in the
Sub-Advisory Agreements for the Sub-Advised Funds.
As to each Fund, the Sub-Advisory
Agreement specifically provides that Alcentra NY assume responsibility for the voting of proxies of companies whose shares are held by
the Fund pursuant to proxy voting procedures approved by BNYM Adviser. The Current Sub-Advisory Agreements did not require Alcentra NY
to assume proxy voting responsibilities without its consent; however, as to each Sub-Advised Fund, Alcentra NY had assumed responsibility
for voting such proxies pursuant to a letter agreement dated April 1, 2020 with BNYM Adviser. As to each Fund, the Sub-Advisory Agreement
also authorizes and obligates Alcentra NY to notify BNYM Adviser if it becomes aware of any bankruptcy proceedings with respect to certain
Fund portfolio securities. As to each Fund, the Sub-Advisory Agreement also includes non-disclosure provisions, contains representations
and warranties made on behalf of BNYM Adviser and Alcentra NY, and sets forth certain governance and notification requirements for BNYM
Adviser and Alcentra NY.
The Sub-Advisory Agreement
for each Fund provides that Alcentra NY will be compensated by BNYM Adviser from the management fee that BNYM Adviser receives from the
Fund. There will be no
increase in the advisory fee paid by the Fund
to BNYM Adviser as a consequence of the implementation of the Sub-Advisory Agreement. Alcentra NY will bear all expenses incurred by it
in connection with the performance of its services under the Sub-Advisory Agreement.
With respect the High
Yield Strategies Fund, the Sub-Advisory Agreement provides that BNYM Adviser pay Alcentra NY a sub-investment advisory fee at
an annual rate of .36% of the value of the High Yield Strategies Fund's average weekly total
assets minus the sum of accrued liabilities (other than the aggregate indebtedness constituting financial leverage).
With respect to each of
the Target Term Fund and Multi-Strategy Fund, the annual fee payable to Alcentra NY by BNYM Adviser under the Sub-Advisory Agreement is
the same as the fee that is payable to Alcentra NY by BNYM Adviser under the Current Sub-Advisory Agreement, and the scope of services
that Alcentra NY is required to provide in managing the Fund's portfolio pursuant to the Sub-Advisory Agreement is the same as the scope
of services provided by Alcentra NY in managing the Fund's portfolio pursuant to the Current Sub-Advisory Agreement.
With respect the Target
Term Fund, the Sub-Advisory Agreement provides that BNYM Adviser pay Alcentra NY a sub-investment
advisory fee at an annual rate of .425% of the average daily value of the Target Term Fund's Managed Assets. For the Target Term Fund's
fiscal year ended August 31, 2021, BNYM Adviser paid Alcentra NY $818,240, pursuant to the
Current Sub-Advisory Agreement.
With respect the Multi-Strategy
Fund, the Sub-Advisory Agreement provides that BNYM Adviser pay Alcentra NY a sub-investment
advisory fee at an annual rate of .625% of the value of the Multi-Strategy Fund's Managed Assets determined as of the last day of each
quarter. For the Multi-Strategy Fund's fiscal year ended March 31, 2022, BNYM Adviser paid Alcentra NY $2,104,383,
pursuant to the Current Sub-Advisory Agreement.
As to each Fund, the Sub-Advisory
Agreement is subject to annual approval by the Board, including a majority of the Independent Board Members. As to each Fund, the Sub-Advisory
Agreement is terminable without penalty by: (i) BNYM Adviser on not more than 60 days' notice to Alcentra NY; (ii) the Board or by vote
of the holders of a majority of the Fund's outstanding voting securities on not more than 60 days' notice to Alcentra NY; or (iii) Alcentra
NY on not less than 90 days' notice to the Fund and BNYM Adviser. As to each Fund, the Sub-Advisory Agreement provides that it will terminate
automatically in the event of its "assignment" as such term is defined under the 1940 Act or the Investment Advisers Act of
1940, as amended. In addition, the Sub-Advisory Agreement provides that it will terminate, as to the relevant Fund, if the Management
Agreement terminates for any reason.
Interim Sub-Advisory Agreement
As the Transaction is not
contingent on shareholder approval of the Sub-Advisory Agreement, it is possible that the Transaction could occur prior to shareholder
approval of the Sub-Advisory Agreement for a Fund, which would terminate the dual employee arrangement with the High Yield Strategies
Fund's portfolio managers and the Current Sub-Advisory Agreement for the Sub-Advised Funds, as the case may be. To ensure that each Fund
is provided with uninterrupted portfolio management after the Closing Date, the Board approved at the August Meeting the Interim Sub-Advisory
Agreement, which will become effective for a Fund only if shareholders have not approved the Sub-Advisory Agreement on or before the Closing
Date. In accordance with the requirements of no-action relief granted by the staff of the Securities and Exchange Commission's Division
of Investment Management and Rule 15a-4 under the 1940 Act, the Interim Sub-Advisory Agreement would have a maximum term of 150 days from
the Closing Date.
As to each Fund, there
are no material differences between the Interim Sub-Advisory Agreement and the Sub-Advisory Agreement, except for the term and termination
provisions. In addition, the Interim Sub-Advisory Agreement contains provisions required by the no-action relief and Rule 15a-4 under
the 1940 Act, which state that the fee payable by BNYM Adviser to Alcentra NY must be paid into an interest-bearing escrow account with
the Fund’s custodian or a bank for the period during which the Interim Sub-Advisory Agreement is in effect. The Sub-Advisory Agreement
will replace the Interim Sub-Advisory Agreement, as to the relevant Fund, if it is approved by shareholders. In the event that the Interim
Sub-Advisory Agreement goes into effect, the relevant Fund would continue to solicit shareholder approval of the Sub-Advisory Agreement.
If shareholders approve the Sub-Advisory Agreement by the end of the 150-day period, the amount in the escrow account (including interest
earned) will be paid to Alcentra NY. If shareholders do not approve the Sub-Advisory Agreement by the end of the 150-day period, Alcentra
NY will be paid, out of the escrow account, the lesser of: (i) Alcentra NY's costs incurred in performing its duties under the Interim
Sub-Advisory Agreement (plus interest earned on that amount while in escrow); or (ii) the total amount in the escrow account (plus interest
earned).
Considerations of the
Board
BNY Mellon publicly announced
the Transaction on May 31, 2022. At the August Meeting, the Board discussed the Transaction and BNYM Adviser recommended, as to each Fund,
the approval of the Interim Sub-Advisory Agreement and the Sub-Advisory Agreement in order to provide continuity of portfolio management
for the Fund after the Closing Date. At the August Meeting, the Board members present at the meeting, including a majority of the Independent
Board Members, unanimously approved, as to each Fund, the Sub-Advisory Agreement and the engagement of Alcentra NY as the Fund's sub-adviser,
subject to shareholder approval, and the Interim Sub-Advisory Agreement that would go into effect for a limited period of time only if
shareholders have not approved the Sub-Advisory Agreement on or before the Closing Date. At the August Meeting, the Board, including a
majority of the Independent Board Members, considered information presented to them as part of the annual agreement review process at
the 15(c) Meeting, as well as information about Alcentra NY and the Transaction received at the August Meeting, and concluded that approval
of these agreements was in the best interests of each Fund and its shareholders.
In connection with the
August Meeting and in accordance with Section 15(c) of the 1940 Act, the Board requested, and BNYM Adviser and Alcentra NY provided, materials
relating to the Transaction, Alcentra NY, Alcentra Group Holdings, Inc. and Franklin Templeton in connection with the Board's consideration
of whether to approve the Sub-Advisory Agreement. This included a description of the Transaction and its anticipated effects on Alcentra
NY as well as information regarding Alcentra Group Holdings, Inc. and its business activities, personnel and affiliates. The Board noted
that, as to each Fund, BNYM Adviser and Alcentra NY represented that there would be no diminution in the nature, extent or quality of
the services provided to the Fund in connection with the implementation of the Sub-Advisory Agreement. Accordingly, the Board also considered
information presented to them as part of the annual agreement review process at the 15(c) Meeting. Additionally, the Board reviewed materials
supplied by counsel that were prepared for use by the Board in fulfilling its duties under state law and the 1940 Act. It was noted that
the Transaction would comply with Section 15(f) of the 1940 Act in that 75% or more of the Board was comprised of Independent Board Members
and would remain so for three years following the Closing Date, and that no "unfair burden" (as defined in the 1940 Act) would
be imposed on any Fund by Alcentra NY during the two-year period following the Closing Date.
In voting to approve the
Sub-Advisory Agreement, the Board considered, as to each Fund, whether the approval of the Sub-Advisory Agreement would be in the best
interests of the Fund and its shareholders, an evaluation based on several factors including those discussed below. The Independent Board
Members were represented by legal counsel that is independent of BNYM Adviser and Alcentra NY in connection
with their consideration of approval of the
Sub-Advisory Agreement and the Interim Sub-Advisory Agreement. The factors discussed below were also considered by the Independent Board
Members in executive session during which such independent legal counsel provided guidance and a written description to the Independent
Board Members of their statutory responsibilities and the legal standards that are applicable to the approval of investment advisory and
sub-investment advisory agreements. Based on their discussions and considerations described below, the Board, including a majority of
the Independent Board Members, approved for each Fund the Sub-Advisory Agreement, subject to shareholder approval, and the Interim Sub-Advisory
Agreement that would go into effect, without shareholder approval, for a limited period of time only if shareholders have not approved
the Sub-Advisory Agreement on or before the Closing Date. It is currently anticipated that the Sub-Advisory Agreement, if approved by
shareholders, will be reviewed by the Board as part of its annual review of advisory arrangements for the relevant Fund in the first quarter
of 2023.
Nature, Extent and Quality
of Services to be Provided under the Sub-Advisory Agreement. In examining the nature, extent and quality of the services to be provided
by Alcentra NY to the relevant Fund under the Sub-Advisory Agreement, the Board considered, as to each Fund, (i) Alcentra NY's organization,
history, reputation, qualification and background, as well as the qualifications of its personnel; (ii) Alcentra NY's expertise in providing
portfolio management services to the Fund and the performance history of the Fund; (iii) Alcentra NY's investment strategy for the Fund;
(iv) the Fund's long- and short-term performance relative to comparable funds and unmanaged indices; and (v) Alcentra NY's compliance
program. The Board specifically took into account that there were currently no long-term or short-term plans to make changes to the investment
policies, strategies or objective of the relevant Fund, or to the status of Messrs. Barris and Cronk as primary portfolio managers of
the Funds, as a result of the Transaction or in connection with the implementation of the Sub-Advisory Agreement. The Board members considered
the specific responsibilities in all aspects of the day-to-day management of the relevant Fund by Alcentra NY, and the fact that existing
management of Alcentra currently expects that the involvement of Messrs. Barris and Cronk in the portfolio management of the Funds will
be unaffected by the Transaction. The Board also considered the financial resources that will be available to Alcentra NY. The Funds'
Chief Compliance Officer discussed the compliance infrastructure of the Funds following the Transaction. The Board also discussed the
acceptability of the terms of the Sub-Advisory Agreement and the Interim Sub-Advisory Agreement.
The Board concluded that,
as to each Fund, the Fund will continue to benefit from the quality and experience of Alcentra NY's investment professionals, specifically
including Messrs. Barris and Cronk, who will continue to provide services to the Fund after the Transaction. Based on its consideration
and review of the foregoing information, the Board concluded that, as to each Fund, it was satisfied with the nature, extent and quality
of the sub-investment advisory services expected to be provided by Alcentra NY.
Fund Investment Performance.
Because existing management of Alcentra currently expects that the involvement of Messrs. Barris and Cronk in the portfolio management
of the Funds will be unaffected by the Transaction, the Board members considered, as to each Fund, the investment performance of those
investment professionals in managing the Fund's portfolio as a factor in evaluating the Sub-Advisory Agreement and the Interim Sub-Advisory
Agreement.
At the 15(c) Meeting, as
to the relevant Fund, the Board received and reviewed reports prepared by Broadridge Financial Solutions, Inc. ("Broadridge"),
an independent provider of investment company data, which included information comparing the Fund's performance with the performance of
a group of funds selected by Broadridge as comparable to the Fund (the "Performance Group") and with a broader group of funds
(the "Performance Universe"), all for various periods ended December 31, 2021. It was noted that, while
the Board has found the Broadridge data generally useful, the Board members recognized the limitations of such data, including that the
data may vary depending on the end date selected and that the
results of the performance comparisons may
vary depending on the selection of the peer group and its composition over time. BNYM Adviser also provided a comparison of each Fund's
calendar year total returns to the returns of the Fund's benchmark index. The Board concluded that it was
generally satisfied with each Fund's overall performance and portfolio management.
At the August Meeting,
the Board reviewed, as to each Fund, updated reports prepared by Broadridge which included information comparing the Fund's performance
with its Performance Group and Performance Universe, all for various periods ended May 31, 2022. BNYM Adviser also provided information
comparing each Fund's performance with its benchmark index and Morningstar category percentile ranking, all for various periods ended
July 31, 2022. The Board discussed with representatives of BNYM Adviser and Alcentra NY the results of the comparisons and considered
each Fund's performance in light of overall financial market conditions. Where a Fund's total return
performance was below the median during specified periods, the Board noted the explanations from BNYM
Adviser and Alcentra NY concerning the Fund's relative performance versus
the Performance Group or Performance Universe for such periods.
Based on its review, the Board concluded that it was generally satisfied with each Fund's overall performance and portfolio management.
The Board members discussed
with representatives of BNYM Adviser and Alcentra NY that the investment strategies to be employed by Alcentra NY in the management of
each Fund's assets are currently expected to remain the same under the Sub-Advisory Agreement. The Board also considered the fact that
existing management of Alcentra currently expects that the involvement of Messrs. Barris and Cronk in the portfolio management of the
Funds will be unaffected by the Transaction. Based on its consideration and review of the foregoing, the Board concluded that, as to each
Fund, these factors supported a decision to approve the Sub-Advisory Agreement and the Interim Sub-Advisory Agreement.
Management Fees and
Sub-Advisory Fees and Expense Ratio. The Board considered the proposed fee payable under each Sub-Advisory Agreement, noting that
the proposed fee would be paid by BNYM Adviser, as is the case under the Current Sub-Advisory Agreements, and, thus, would not impact
the fees paid by the relevant Fund. At the 15(c) Meeting, the Board reviewed and considered, as to the relevant Fund, the contractual
management fee payable by the Fund to BNYM Adviser pursuant to the Management Agreement and, in the case of each Sub-Advised Fund, the
fee payable by BNYM Adviser to Alcentra NY pursuant to the Current Sub-Advisory Agreement. As to each Fund, the Board also reviewed reports
prepared by Broadridge which included information comparing the Fund's actual and contractual management fees and total expenses with
those of the same group of funds in the Performance Group (the "Expense Group") and with a broader group of funds (the "Expense
Universe"), the information for which was derived in part from fund financial statements available to Broadridge as of the date of
its analysis. The Board also reviewed the range of actual and contractual advisory fees and total expenses of the Expense Group and Expense
Universe funds and discussed the results of the comparisons. The Board concluded that the fees paid to BNYM Adviser were appropriate under
the circumstances and in light of the factors and the totality of the services provided.
At the August Meeting,
the Board considered, as to each Fund, the proposed fee payable to Alcentra NY under the Sub-Advisory Agreement in relation to the fee
paid to BNYM Adviser by the Fund and the respective services provided by Alcentra NY and BNYM Adviser. The Board noted, with respect to
the Sub-Advised Funds, that the proposed fee would be the same as that payable under the Current Sub-Advisory Agreement for each such
Fund, and that the proposed fee would be paid by BNYM Adviser, as is the case under the Current Sub-Advisory Agreements, and, thus, would
not impact the fees paid by the Funds. As to each Fund, the Board reviewed updated reports prepared by Broadridge which included information
comparing the Fund's actual and contractual management fees and total expenses with those of its Expense Group and Expense Universe, the
information for which was derived in part from fund financial statements available to Broadridge as of the date of its analysis. The Board
also reviewed the range of
actual and contractual advisory fees and total
expenses of the Expense Group and Expense Universe funds and discussed the results of the comparisons. The Board determined that, as to
each Fund, the advisory fees and other expenses continued to be reasonable in light of the nature, extent
and quality of the services to be provided to the Fund under the Management Agreement and Sub-Advisory Agreement.
The Board concluded that, as to each Fund, the proposed fee payable by BNYM Adviser to Alcentra NY in its capacity as sub-investment adviser
was reasonable and appropriate.
Profitability. The
Board recognized that, because the proposed fee payable under the Sub-Advisory Agreement to Alcentra NY would be paid by BNYM Adviser,
and not the relevant Fund, an analysis of profitability was more appropriate in the context of the Board's consideration of the Management
Agreement. At the 15(c) Meeting, the Board received and considered, as to the relevant Fund, a profitability analysis of BNYM Adviser
and its affiliates in providing services to the Fund. BNYM Adviser representatives reviewed the expenses allocated and profit received
by BNYM Adviser and its affiliates and the resulting profitability percentage for managing each Fund and the aggregate profitability percentage
to BNYM Adviser and its affiliates for managing the funds in the BNY Mellon fund complex, and the method used to determine the expenses
and profit. The Board concluded that the profitability results were not excessive, given the services rendered and service levels provided
by BNYM Adviser and its affiliates.
At the August Meeting,
the Board noted that, as to each Fund, because Alcentra NY would no longer be an affiliate of BNYM Adviser after the Closing Date, the
fee payable to Alcentra NY by BNYM Adviser under the Sub-Advisory Agreement would have the effect of potentially reducing BNYM Adviser's
profitability with respect to the Fund. Therefore, the Board determined that BNYM Adviser's expected profitability should not be excessive
in light of the nature, extent and quality of the services to be provided to the Fund after the Transaction. Consideration of profitability
with respect to Alcentra NY was not relevant to the Board's determination to approve the Sub-Advisory Agreement and the Interim Sub-Advisory
Agreement.
Economies of Scale.
The Board recognized that, because the proposed fee payable under the Sub-Advisory Agreement to Alcentra NY would be paid by BNYM Adviser,
and not the relevant Fund, an analysis of economies of scale was more appropriate in the context of the Board's consideration of the Management
Agreement. At the 15(c) Meeting, the Board discussed, as to the relevant Fund, any economies of
scale or other efficiencies that may result from increases in a Fund's assets. The
Board noted that there are various ways to share potential economies of scale with Fund shareholders and that it appeared that the benefits
of any economies of scale would be appropriately shared with shareholders.
At the August Meeting,
the Board concluded that no material impact to the analysis of economies of scale is expected as a result of the Transaction and that,
to the extent in the future it were determined that material economies of scale had not been shared with a Fund, the Board would seek
to have those economies of scale shared with the Fund.
Other Benefits to Alcentra
NY. At the August Meeting, the Board considered, as to the relevant Fund, potential benefits to Alcentra NY from acting as sub-investment
adviser and noted that no such ancillary benefits were indicated. At the August Meeting, the Board also considered the benefits to be
received by BNY Mellon and Alcentra NY as a result of the Transaction and determined that any such ancillary benefits were reasonable.
After full consideration
of the factors discussed above, with no single factor identified as being of paramount importance, as to each Fund, the Board, including
a majority of the Independent Board Members, approved, and recommends that shareholders of the Fund approve, the Sub-Advisory Agreement
for the Fund.
Section 15(f) of the 1940 Act
With respect to each Fund,
the Transaction was structured in reliance upon Section 15(f) of the 1940 Act. Section 15(f) of the 1940 Act provides, in part, that when
a sale of an interest in an investment adviser of a registered investment company occurs, the investment adviser or any of its affiliated
persons may receive any amount or benefit in connection with the sale so long as two conditions are satisfied. The first condition of
Section 15(f) is that during the three-year period following the completion of the transaction, at least 75% of the investment company's
board of directors must not be "interested persons" (as defined in the 1940 Act) of the investment adviser or predecessor adviser.
Second, an "unfair burden" (as defined in the 1940 Act) must not be imposed on the investment company as a result of the transaction
relating to the sale of such interest, or any express or implied terms, conditions or understandings applicable thereto. The term "unfair
burden" includes any arrangement during the two-year period after the transaction whereby the investment adviser (or predecessor
or successor adviser), or any "interested person" (as defined in the 1940 Act) of such an adviser, receives or is entitled to
receive any compensation, directly or indirectly, from the investment company or its security holders (other than fees for bona fide investment
advisory or other services) or from any person in connection with the purchase or sale of securities or other property to, from or on
behalf of the investment company (other than bona fide ordinary compensation as principal underwriter for the investment company). BNYM
Adviser, Alcentra, Franklin Templeton and each Fund have agreed to comply with the conditions of Section 15(f) of the 1940 Act.
* * *
REQUIRED VOTE
AND THE BOARD'S RECOMMENDATION
As to each Fund, the approval
of the Sub-Advisory Agreement requires the affirmative vote of a majority of the Fund's outstanding voting securities (as defined in the
1940 Act). Such a majority means the affirmative vote of the holders of (a) 67% or more of the shares of the Fund present, in person or
represented by proxy, at the Meeting, if the holders of more than 50% of the outstanding shares of the Fund are so present, or (b) more
than 50% of the outstanding shares of the Fund, whichever is less.
THE BOARD MEMBERS PRESENT
AT THE AUGUST MEETING, INCLUDING A MAJORITY OF THE INDEPENDENT BOARD MEMBERS, UNANIMOUSLY RECOMMEND THAT SHAREHOLDERS VOTE "FOR"
APPROVAL OF THE Sub-Advisory Agreement.
* * *
VOTING INFORMATION
Quorum, Proxies and Voting at the Meeting
As to each Fund, a quorum
is constituted for the Fund by the presence in person or by proxy of the holders of a majority of
the Fund's outstanding shares entitled to vote at the Meeting. Virtual attendance at the Meeting shall constitute in person attendance
for purposes of calculating a quorum. If a quorum is not present at the Meeting for a Fund, or if a quorum is present but sufficient votes
to approve the proposal for the Fund are not received, the persons named as proxies may propose one or more adjournments of the Meeting
to permit further solicitation of proxies for the Fund. In determining whether to adjourn the Meeting with respect to the proposal for
a Fund, the following factors may be considered: the nature of the proposal, the percentage of favorable votes actually cast, the percentage
of negative votes actually cast, the nature of any further solicitation and the information to be provided to Fund shareholders with respect
to the reasons for the solicitation. Any adjournment will require the affirmative vote by the holders of a
majority of such Fund's shares eligible to
vote that are represented at the Meeting virtually or by proxy. If a quorum is present, the persons named as proxies will vote those proxies
which they are entitled to vote "FOR" the proposal in favor of such adjournment, and will vote those proxies required to be
voted "AGAINST" the proposal against any adjournment.
If
you hold your shares directly (not through a broker-dealer or other intermediary), and if you return a signed proxy card that does not
specify how you wish to vote on the proposal, your shares will be voted "FOR" the proposal. If a proxy is properly executed
and returned marked with an abstention, the Fund shares represented thereby will be considered to be present at the Meeting for that Fund
for purposes of determining the existence of a quorum for the transaction of business. Abstentions will not constitute a vote "FOR"
the proposal. For this reason, abstentions will have the effect of a "no" vote for the purpose of obtaining the requisite approval
for the proposal.
Broker-dealer
firms holding shares of a Fund in "street name" for
the benefit of their clients will request the instructions of such clients on how to vote their shares before the Meeting. A broker-dealer
that is a member of the New York Stock Exchange and that has not received instructions from a client prior to the date specified in the
broker-dealer firm's request for voting instructions may not submit a proxy on behalf of
such client's shares with respect the proposal. Ordinarily, broker non-votes, if any, would
be counted as shares present and entitled to vote for purposes of determining whether a quorum is present, but would not be counted as
a vote in favor of the proposal. However, because the proposal is considered non-routine, broker non-votes are inapplicable to this solicitation
and will have no impact on establishing quorum or the votes cast for or against the proposal.
If
you hold shares of a Fund through a broker-dealer (that is not a member of the New York Stock Exchange)
or other intermediary that has entered into a service agreement with the Fund or the Fund's distributor, such intermediary may be the
record holder of your shares. At the Meeting, an intermediary will vote shares for which it receives instructions from its customers in
accordance with those instructions. A signed proxy card or other authorization by a shareholder that does not specify how the shareholder's
shares should be voted on the proposal may be deemed to authorize the intermediary to vote such shares in favor of the proposal. Depending
on its policies, applicable law or contractual or other restrictions, an intermediary may be permitted to vote shares with respect to
which it has not received voting instructions from its customers. In those cases, the intermediary may, but may not be required to, vote
such shares in the same proportion as those shares for which the intermediary has received voting instructions. Because of this practice,
a small number of shareholders could determine how a Fund votes, if other shareholders fail to vote.
With respect to BNYM Adviser-sponsored
IRAs, the Individual Retirement Custodial Account Agreement governing the IRAs requires BNY Mellon, as the custodian of the IRAs, to vote
Fund shares held in such IRAs in accordance with the IRA shareholder's instructions. BNY Mellon will solicit instructions from such IRA
shareholders. To be effective, voting instructions must be received prior to the close of business on October 11, 2022. However, if no
voting instructions are received, BNY Mellon may vote Fund shares held in the IRA in the same proportions as the Fund shares for which
voting instructions are received from other BNYM Adviser-sponsored IRA shareholders. Therefore, if an IRA shareholder does not provide
voting instructions prior to the Meeting, BNY Mellon will vote the IRA shares in the same proportions as it votes the shares for which
properly conveyed instructions are timely received from other BNYM Adviser-sponsored IRA shareholders. Because of this practice, a small
number of shareholders could determine how the Fund votes, if other shareholders fail to vote.
If
you beneficially own shares that are held in "street name" through
a broker-dealer or that are held of record by a bank or other intermediary, and you do not give specific voting instructions for your
shares, they may not be voted at all or, as described above, they may be voted in a manner that you may not intend.
Therefore, you are strongly encouraged to give
your broker-dealer, bank or intermediary specific instructions as to how you want your shares to be voted.
Methods of
Solicitation and Expenses
The cost of preparing,
printing and mailing this Joint Proxy Statement and the attached Notice of Special Joint Meeting of Shareholders and the accompanying
proxy card(s), as well as the costs associated with the proxy solicitation, which is estimated to total approximately $285,000, will be
borne by BNYM Adviser and not the Funds. These costs will be borne by BNYM Adviser whether
or not the Sub-Advisory Agreement is approved. Solicitation may be made by officers or employees
of BNYM Adviser or Alcentra, or by dealers and their representatives. In addition
to the use of the mail, proxies may be solicited personally or by telephone, and BNYM Adviser may pay persons holding Fund shares in their
names or those of their nominees for their expenses in sending soliciting materials to their principals. BNYM Adviser will retain AST
Fund Solutions, LLC (the "Proxy Solicitor") to assist in the solicitation of proxies, primarily by contacting shareholders by
telephone. The cost of the Proxy Solicitor is estimated to be approximately $88,100, which amount is included in the estimated total expenses
listed above.
Authorizations to execute
proxies may be obtained by telephonic or electronically transmitted instructions in accordance with procedures designed to authenticate
the shareholder's identity. In all cases where a telephonic proxy is solicited (as opposed to where the shareholder calls the toll-free
telephone number directly to vote), the shareholder will be asked to provide or confirm certain identifiable information and to confirm
that the shareholder has received the Joint Proxy Statement and proxy card(s). Within 72 hours of receiving such telephonic or electronically
transmitted voting instructions from a shareholder, a confirmation will be sent to the shareholder to ensure that the vote has been taken
in accordance with the shareholder's instructions and to provide a telephone number to call immediately if the shareholder's instructions
are not correctly reflected in the confirmation. Any Fund shareholder giving a proxy by telephone or electronically may revoke it at any
time before it is exercised by sending a written notice of revocation to the proxy tabulator at the address listed on the proxy card,
by submitting a new proxy to the Fund or by attending the Meeting and voting virtually.
* * *
ADDITIONAL INFORMATION
Custodian and
Transfer and Dividend-Paying Agent and Registrar
BNY Mellon, located at
240 Greenwich Street, New York, New York 10286, serves as custodian for the assets of each Fund pursuant to a custody agreement. For the
respective Fund's most recent fiscal year, BNY Mellon charged the High Yield Strategies Fund, Target Term Fund and Multi-Strategy Fund,
$16,064, $208,723 and $125,343, respectively, pursuant to the custody agreement.
Computershare Inc., located
at 480 Washington Boulevard, Jersey City, New Jersey 07310, acts as each Fund's Transfer Agent, Dividend-Paying Agent and Registrar.
Payments to
Affiliated Brokers
As to each Fund,
during the Fund's most recent fiscal year, the Fund did not pay any commissions to affiliated brokers.
* * *
OTHER MATTERS
The Board is not aware
of any other matters that may come before the Meeting. However, should any such matters properly come before the Meeting, it is the intention
of the persons named in the accompanying form of proxy to vote the proxy in accordance with their judgment on such matters.
Each of the High Yield
Strategies Fund and the Target Term Fund holds annual meetings of shareholders. The Multi-Strategy Fund
is not required to hold an annual meeting in any year in which the election of directors is not required to be acted upon under the 1940
Act.
With respect to the High
Yield Strategies Fund and the Target Term Fund, any proposals of shareholders that are intended to be presented at the relevant Fund's
2023 Annual Meeting of Shareholders in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), must be received by the Secretary of such Fund at the Fund's principal executive offices no later than March 7, 2023, in the
case of the High Yield Strategies Fund, or January 2, 2023, in the case of the Target Term Fund, and must comply with all other legal
requirements in order to be included in the Fund's proxy statement and form of proxy for that meeting. For other shareholder proposals
to be presented at the 2023 Annual Meeting of Shareholders (but not included in the Fund's proxy statement), a shareholder's notice must
be delivered to the Secretary of the relevant Fund at the Fund's principal executive offices no earlier than February 5, 2023, in the
case of the High Yield Strategies Fund, or December 3, 2022, in the case of the Target Term Fund, and no later than 5:00 p.m., Eastern
time, on March 7, 2023 January 2, 2023, respectively. If the 2023 Annual Meeting of Shareholders is advanced or delayed by more than 30
days from August 16, 2023, in the case of the High Yield Strategies Fund, or June 16, 2023, in the case of the Target Term Fund, then
timely notice must be delivered not earlier than the 150th day prior to such annual meeting and not later than 5:00 p.m., Eastern
time, on the later of the 120th day prior to such annual meeting or the tenth day following the day on which public announcement
of the date of such meeting is first made. All shareholder proposals must include the information required by the relevant Fund's bylaws.
With respect to the Multi-Strategy
Fund, any shareholder proposal for inclusion in a proxy statement for the Fund's next shareholder
meeting subsequent to this Meeting, if any, must be received by the Fund's Secretary at the offices of the Fund, 240 Greenwich Street,
New York, New York 10286, in a reasonable period of time before the Fund begins to print and mail the proxy materials for such meeting.
Under the proxy rules of the Securities and Exchange Commission, shareholder proposals meeting requirements contained in those rules may,
under certain conditions, be included in the Fund's proxy materials for a particular meeting of shareholders. One of these conditions
relates to the timely receipt by the Fund of any such proposal. The fact that the Fund receives a shareholder proposal in a timely manner
does not, however, ensure its inclusion in the Fund's proxy materials since there are other requirements in the proxy rules relating to
such inclusion.
* * *
IT IS IMPORTANT THAT PROXIES
BE RETURNED PROMPTLY. THEREFORE, SHAREHOLDERS WHO DO NOT EXPECT TO ATTEND THE MEETING VIRTUALLY ARE URGED TO COMPLETE, SIGN, DATE AND
RETURN THE PROXY CARD(S) IN THE ENCLOSED POSTAGE-PAID ENVELOPE OR OTHERWISE VOTE PROMPTLY.
Dated: August 26, 2022
SCHEDULE 1
PERTAINING TO SHARE OWNERSHIP
Set forth below for each
Fund is information as to the number of shares of the Fund outstanding and those shareholders, if any, known by the Fund to beneficially
own 5% or more of the Fund's outstanding voting securities (including series thereof) as of July 31, 2022.
Name of Fund
Number of Shares Outstanding |
Name and Address of
Beneficial Owner |
Number of Shares
Owned |
Percent of Shares Held |
BNY Mellon High Yield Strategies Fund
72,736,534 |
First Trust Portfolios L.P.
First Trust Advisors L.P.
The Charger Corporation
120 East Liberty Drive, Suite 400
Wheaton, Illinois 60187 |
11,499,8771 |
15.81%1 |
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
15,000,726 |
Morgan Stanley
1585 Broadway
New York. NY 10036 |
1,122,1412 |
7.5%2 |
|
Janney Montgomery Scott LLC
1717 Arch Street
Philadelphia, PA 19103 |
949,4523 |
6.3%3 |
BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc.
2,222,132 |
Morgan Stanley Smith Barney LLC
2000 Westchester Avenue
Purchase, NY 10577 |
160,000 |
7.2% |
___________________
1 As stated in Schedule 13g filed with the SEC on January 12, 2022.
2 As stated in Schedule 13g filed with
the SEC on February 9, 2022.
3 As stated in Schedule 13g filed
with the SEC on January 5, 2022.
As
of July 31, 2022, the Target Term Fund had 15,000,726.768 shares of common stock, the Multi-Strategy had 2,222,132 shares of common stock
and the High Yield Strategies Fund had 72,736,534 shares of beneficial interest issued and outstanding. Cede & Co., P.O. Box 20, Bowling
Green Station, New York, New York 10274, held of record 100% of the Target Term Fund's outstanding shares of common stock, 99.88% of the
Multi-Strategy Fund's outstanding shares of common stock and 99.40% of the High Yield Strategies Fund's outstanding shares of beneficial
interest.
As
of July 31, 2022, Board members and officers of the Funds, as a group, owned less than 1% of each Fund's outstanding voting shares.
Under
the 1940 Act, a shareholder that beneficially owns, directly or indirectly, more than 25% of a Fund's voting securities may be deemed
a "control person" (as defined in the 1940 Act) of the Fund.
Delinquent Section 16(a) Reports
As to each of the High Yield Strategies Fund
and the Target Term Fund, under Section 16(a) of the Exchange Act and Section 30(h) of the 1940 Act, and the rules thereunder, the Fund's
officers and Board members, persons owning more than 10% of the Fund's shares, and certain additional persons are required to report their
transactions in the Fund's shares to the SEC and the Fund. Based solely on written
representations of such persons and on copies of reports
that have been filed with the SEC, the High Yield Strategies Fund believes that, during the fiscal year ended August 31, 2021, all filing
requirements applicable to such persons were complied with, except that Form 3s were not filed on a timely basis for BNYM Adviser and
Bradley Skapyak, who became a Board member of the Fund on September 16, 2021. With respect to BNYM Adviser, a Form 3 was filed October
12, 2021, and with respect to Mr. Skapyak, a Form 3 was filed on September 27, 2021, each of which reflected that BNYM Adviser and Mr.
Skapyak, as applicable, did not own any of the High Yield Strategies Fund's shares of beneficial interest. With respect to the Target
Term Fund, based solely on written representations of such persons and on copies of reports that have been filed with the SEC, the Target
Term Fund believes that, during the fiscal year ended March 31, 2022, all filing requirements applicable to such persons were complied
with, except that Form 3s were not filed on a timely basis for BNYM Adviser and Alcentra NY. BNYM Adviser and Alcentra NY filed their
Form 3s on October 12, 2021 and October 4, 2021, respectively, reflecting that they did not own any shares of the Target Term Fund's common
stock.
EXHIBIT A
FORM OF SUB-ADVISORY AGREEMENT
BNY MELLON INVESTMENT
ADVISER, INC.
240 Greenwich Street
New York, New York 10286
[________],
202[_]
Alcentra NY, LLC
200 Park Avenue
New York, New York 10166
Ladies and Gentlemen:
As you are aware, [BNY
Mellon High Yield Strategies Fund / BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. / BNY Mellon Alcentra Global
Multi-Strategy Credit Fund, Inc.] (the "Fund") desires to employ its capital by investing and reinvesting the same in investments
of the type and in accordance with the limitations specified in the Fund's Prospectus [and Statement of Additional Information] as from
time to time in effect, copies of which have been or will be submitted to you, and in such manner and to such extent as from time to time
may be approved by the Fund's Board. The Fund employs BNY Mellon Investment Adviser, Inc. (the "Manager") to act as the Fund's
investment manager pursuant to a written agreement (the "Management Agreement"), a copy of which has been furnished to you.
The Manager is authorized to and desires to retain you, and you hereby agree to accept such retention, to act as the Fund's sub-investment
adviser as of the date set forth above (the "Effective Date").
In connection with your
serving as sub-investment adviser to the Fund, it is understood that from time to time you will employ or associate with yourself such
person or persons as you may believe to be particularly fitted to assist you in the performance of this Agreement. The compensation of
such person or persons shall be paid by you and no obligation may be incurred on the Fund's behalf in any such respect.
Subject to the supervision
and approval of the Manager and the Fund's Board, you will provide investment management of the Fund's portfolio subject to and in accordance
with (i) the Fund's investment objectives, policies and limitations as stated in the Fund's Prospectus [and Statement of Additional Information]
as from time to time in effect and provided to you by the Manager; (ii) any applicable procedures or policies adopted or approved by the
Manager or the Fund's Board with respect to the Fund as from time to time in effect and furnished in writing to you; (iii) the requirements
applicable to registered investment companies under applicable laws, including without limitation the Investment Company Act of 1940,
as amended (the "Investment Company Act"), and the rules and regulations thereunder, and the Internal Revenue Code of 1986,
as amended (the "Internal Revenue Code"), and the rules and regulations thereunder applicable to qualification as a "regulated
investment company"; and (iv) any written instructions which the Manager or the Fund's Board may issue to you from time to time;
provided, however, that you shall not be bound by any update, modification or amendment of such documents or other procedures or policies
of the Fund or the Manager unless and until you have been given notice thereof in accordance with this Agreement and have been provided
with a written copy of such update, modification or amendment. With respect to the foregoing, the Manager will seek to provide you with
prior notice of
any update, modification or amendment of such
documents or other procedures or policies of the Fund or the Manager that is reasonably sufficient to provide you with the time necessary
to make any changes to the Fund's portfolio that are required to comply with such procedures or policies in an orderly manner. In connection
with your duties hereunder, you (a) will obtain and provide investment research and supervise the Fund's investments and (b) will conduct
a continuous program of investment, evaluation and, if appropriate, sale and reinvestment of the Fund's assets, including the placing
of portfolio transactions for execution either directly with the issuer or with any broker or dealer. You agree that, in placing any orders
with selected brokers and dealers, you will attempt to obtain the best net result in terms of price and execution. Consistent with this
obligation and in accordance with applicable securities laws, you, in your discretion, may purchase and sell portfolio securities from
and to brokers and dealers who provide the Fund, the Manager's other clients, or your other clients with research, analysis, advice and
similar services. You may cause the Fund to pay to brokers and dealers, in return for such research and analysis, a higher commission
or spread than may be charged by other brokers and dealers, subject to your good faith determination that such commission or spread is
reasonable in terms either of the particular transaction or of your overall responsibility to the Fund and your other clients and that
the total commissions or spreads paid by the Fund will be reasonable in relation to the benefits to the Fund over the long term and, if
applicable, subject to compliance with Section 28(e) of the Securities Exchange Act of 1934, as amended. Such authorization is subject
to termination at any time by the Fund's Board for any reason. In addition, you are authorized to allocate purchase and sale orders for
portfolio securities to brokers and dealers that are affiliated with you, the Manager or the Fund's principal underwriters, if any, if
you believe that the quality of the transaction and the commission are comparable to what they would be with other qualified firms, and
provided that the transactions are consistent with the Fund's Rule 17e-1 procedures as they may be provided to you by the Manager from
time to time. In no instance may portfolio securities be purchased from or sold to you, the Manager, the Fund's principal underwriters,
if any, or any person affiliated with you, the Manager, the Fund's principal underwriters, if any, or the Fund, except in accordance with
the applicable securities laws and the rules and regulations thereunder, including Rules 17a-7 and 17a-10 under the Investment Company
Act and any exemptive order then currently in effect. The Manager will periodically provide you with a list of the affiliates of the Manager
or the Fund to which investment or trading restrictions apply, and will specifically identify in writing (a) all publicly traded companies
in which the Fund may not invest, together with ticker symbols for all such companies, and (b) any affiliated brokers and any restrictions
that apply to the use of those brokers by the Fund.
You shall be deemed to
be an independent contractor and shall, unless otherwise expressly provided or authorized, have no authority to act for or represent the
Manager or the Fund in any way or otherwise be deemed an agent of the Manager or the Fund, and nothing in this Agreement shall be construed
as making the Manager or the Fund a partner or co-venturer with you or any of your affiliates. You shall utilize counterparties for brokerage,
futures and options clearing, ISDA purposes and trade execution under agreements set up in the name of the Fund. You shall be responsible
for managing any collateral and margin requirements associated with investments made for the Fund.
Proxies of companies whose
shares are part of the Fund's assets shall be voted as described in the Fund's Prospectus [and Statement of Additional Information], and
you shall assume responsibility for the voting of such proxies pursuant to proxy voting procedures approved by the Manager. You are authorized
and agree to act on behalf of the Fund with respect to any reorganizations, exchange offers and other voluntary corporate actions and
any amendments to credit agreements in connection with securities held by the Fund in such manner as you deem advisable, unless the Fund
or the Manager otherwise specifically
directs in writing. You shall have no responsibility
with respect to the collection of income, physical acquisition or the safekeeping or custody of the Fund's assets. The Manager shall furnish
you with copies of the Fund's Prospectus[es, Statements of Additional Information] and shareholder reports. You will be provided the opportunity
to review and approve any description of you and your investment process set forth in the Fund's Prospectus[, Statement of Additional
Information] and shareholder reports. The Manager also will furnish you with copies of press releases and shareholder reports that disclose
any changes to the Fund's investment objectives, policies, strategies or restrictions.
You will furnish to the
Manager or the Fund such information, with respect to the investments which the Fund may hold or contemplate purchasing, as the Manager
or the Fund may reasonably request. The Fund and the Manager wish to be informed of important developments materially affecting the Fund's
assets and shall expect you, on your own initiative, to furnish to the Fund or the Manager from time to time such information as you may
believe appropriate for this purpose. In connection therewith, you will notify the Manager if you become aware of any bankruptcy proceedings,
securities litigation class actions or settlements affecting investments which the Fund holds or held at a time relevant to such proceedings,
class actions or settlements. Upon reasonable request, you will make available your officers and employees, including the portfolio managers
named in the Fund's Prospectus [and/or Statement of Additional Information], to meet with the Fund's Board and/or the Manager to review
the Fund's assets.
You will maintain all required
books and records with respect to the securities transactions of the Fund in accordance with all applicable laws, and in compliance with
the applicable requirements of the rules under Section 31 of the Investment Company Act, and will furnish the Fund's Board and the Manager
with such periodic and special reports as the Fund's Board or the Manager reasonably may request. You hereby agree that all records which
you maintain for the Fund or the Manager are the property of the Fund or the Manager, and agree to preserve for the periods prescribed
by applicable law any records which you maintain for the Fund or the Manager and which are required to be maintained, and further agree
to surrender promptly to the Fund or the Manager any records which you maintain for the Fund or the Manager upon request by the Fund or
the Manager, provided that you shall have reasonable opportunity to create and maintain copies of applicable records.
The
Manager (i) is registered as an investment adviser under the Investment Advisers Act of 1940, as amended (the "Investment
Advisers Act"), and will continue to be so registered for so long as this Agreement remains
in effect; (ii) is not prohibited by the Investment Company Act, the Investment Advisers
Act or other law, regulation or order from performing its obligations under this Agreement; (iii) has met, and will seek to continue
to meet for so long as this Agreement is in effect, any other applicable federal or state requirements, or the applicable requirements
of any regulatory or industry self-regulatory agency, necessary to be met in order to perform its obligations under this Agreement; (iv)
has the power and authority to enter into and perform its obligations under this Agreement; and (v) will promptly notify you of the occurrence
of any event that would disqualify the Manager from serving as the investment adviser of an investment company pursuant to Section 9(a)
of the Investment Company Act or otherwise. The Manager will also promptly notify you if
it is served or otherwise receives notice of any action, suit, proceeding, inquiry or investigation, at law or in equity, before or by
any court, public board or body, involving the affairs of the Fund and affecting you; provided, however, that routine regulatory examinations
not involving you shall not be required to be reported by this provision.
You
represent that you (i) are registered as an investment adviser under the Investment Advisers Act and will continue to be so registered
for so long as this Agreement remains in effect; (ii) are not prohibited by the Investment Company Act,
the Investment Advisers Act or other law, regulation or order from performing your obligations under this Agreement; (iii) have met, and
will seek to continue to meet for so long as this Agreement remains in effect, any other applicable federal or state requirements, or
the applicable requirements of any regulatory or industry self-regulatory agency, necessary to be met in order to perform your obligations
under this Agreement; (iv) have the power and authority to enter into and perform your obligations under this Agreement; and (v) will
promptly notify the Manager of the occurrence of any event that would disqualify you from serving as an investment adviser of an investment
company pursuant to Section 9(a) of the Investment Company Act or otherwise.
The Manager and you each
agree to comply with applicable laws, rules and regulations, including the Investment Advisers Act and the Investment Company Act. You
will promptly notify the Fund's Chief Compliance Officer (a) in the event the Securities and Exchange Commission or other governmental
authority has censured you, placed limitations upon your activities, functions or operations, suspended or revoked your registration,
as an investment adviser, or has commenced proceedings or an investigation that may result in any of these actions; or (b) upon becoming
aware of any material fact relating to you that is not contained in the Fund's Prospectus [or Statement of Additional Information], and
is required to be stated therein or necessary to make the statements therein not misleading, or of any statement contained therein that
becomes untrue in any material respect. Upon request, and in accordance with the scope of your obligations and responsibilities contained
in this Agreement, you will provide reasonable assistance to the Fund in connection with the Fund's compliance with applicable provisions
of the Sarbanes-Oxley Act of 2002 and the rules and regulations thereunder, and Rule 38a-1 under the Investment Company Act. Such assistance
shall include, but not be limited to, (i) providing the Fund's Chief Compliance Officer upon request with copies of your compliance policies
and procedures; (ii) certifying periodically, upon the request of the Fund's Chief Compliance Officer, that you are in compliance with
all applicable "federal securities laws," as required by Rule 38a-1 under the Investment Company Act and Rule 206(4)-7 under
the Investment Advisers Act; (iii) facilitating and cooperating with the Fund's Chief Compliance Officer to evaluate the effectiveness
of your compliance controls; (iv) providing the Fund's Chief Compliance Officer with direct access to your compliance personnel; (v) providing
the Fund's Chief Compliance Officer with periodic reports; and (vi) promptly providing the Fund's Chief Compliance Officer with special
reports in the event of material compliance violations. Upon request, you will provide certifications to the Fund, in a form satisfactory
to the Fund, to be relied upon by the Fund's officers certifying the Fund's periodic reports on Form N-CSR pursuant to Rule 30a-2 under
the Investment Company Act.
[From the New Sub-Advisory
Agreement for the High Yield Strategies Fund] In consideration of services rendered pursuant to this Agreement, the Manager
will pay you on the first business day of each month, out of the management fee it receives and only to the extent thereof, a fee at the
annual rate of .36 of 1% of the value of the Fund's average weekly total assets minus the sum of accrued
liabilities (other than the aggregate indebtedness constituting financial leverage) (the "Managed Assets"). Managed
Assets will be computed on such days and at such time or times as described in the Fund's then-current prospectus. If the Manager
waives all or a portion of the management fee it is entitled to receive from the Fund, the fee payable to you pursuant to this Agreement
may be reduced as you and the Manager mutually agree. The fee for the period from the Effective Date to the end of the month thereof shall
be pro-rated according to the proportion which such period bears to the full monthly period, and upon any termination of this Agreement
before the end of any month, the fee for such part of a month shall be pro-rated according to the
proportion which such period bears to the full
monthly period and shall be payable within 10 business days of the date of termination of this Agreement. For the purpose of calculating
the fee payable to you, the value of the Fund's Managed Assets shall be computed in the manner specified
in the Fund's then-current Prospectus.
Net asset value shall be
computed on such days and at such time or times as described in the Fund's then-current Prospectus. You agree to monitor the Fund's assets
and to notify the Manager on any day that you determine that a significant event has occurred with respect to one or more securities held
in the Fund's portfolio that would materially affect the value of such securities (provided that you shall not be responsible for providing
information based on valuations provided by third party services which value securities based upon changes in one or more broad-based
indices). At the request of the Manager, the Fund's Valuation Committee or the Board, you agree to provide additional reasonable assistance
to the Manager, the Fund's Valuation Committee, the Board and the Fund's pricing agents in valuing the Fund's assets, including in connection
with fair value pricing of the Fund's assets.]
[From the New Sub-Advisory
Agreement for the Target Term Fund] [In consideration of services rendered pursuant to this Agreement, the Manager will
pay you on the first business day of each month, out of the management fee it receives and only to the extent thereof, a fee at the annual
rate of 0.425% of the average daily value of the Fund's Managed Assets. "Managed Assets" are the total assets of the Fund, including
any assets attributable to leverage (i.e., any loans from certain financial institutions and/or the issuance of debt securities (collectively,
"Borrowings"), preferred stock or other similar preference securities ("Preferred Shares"), or the use of derivative
instruments that have the economic effect of leverage), minus the Fund's accrued liabilities, other than any liabilities or obligations
attributable to leverage obtained through (i) indebtedness of any type (including, without limitation, Borrowings), (ii) the issuance
of Preferred Shares, and/or (iii) any other means, all as determined in accordance with generally accepted accounting principles.
The fee for the period
from the Effective Date to the end of the month thereof shall be pro-rated according to the proportion which such period bears to the
full monthly period, and upon any termination of this Agreement before the end of any month, the fee for such part of a month shall be
pro-rated according to the proportion which such period bears to the full monthly period and shall be payable within 10 business days
of the date of termination of this Agreement. If the Manager waives all or a portion of the management fee it is entitled to receive from
the Fund, the fee payable to you pursuant to this Agreement may be reduced as you and the Manager mutually agree.]
[[From the New Sub-Advisory
Agreement for the Multi-Strategy Fund] [In consideration of services rendered pursuant to this Agreement, the Manager
will pay you, out of the management fee it receives and only to the extent thereof, a fee, payable quarterly in arrears, computed at the
annual rate of 0.625% of the value of the Fund's Managed Assets determined as of the last day of each quarter as set forth herein. "Managed
Assets" are the total assets of the Fund, including any assets attributable to leverage (i.e., any loans from certain financial institutions
and/or the issuance of debt securities (collectively, "Borrowings"), preferred stock or other similar preference securities
("Preferred Shares"), or the use of derivative instruments that have the economic effect of leverage), minus the Fund's accrued
liabilities, other than any liabilities or obligations attributable to leverage obtained through (i) indebtedness of any type (including,
without limitation, Borrowings), (ii) the issuance of Preferred Shares, and/or (iii) any other means, all as determined in accordance
with generally accepted accounting principles.
The fee will be calculated
and payable to you by the Manager on a quarterly basis. The fee for each quarter will be calculated at the time the Fund's net asset value
is determined for purposes of the Investment Company Act and before giving effect to any share repurchases during such quarter. The fee
will be paid to you by the Manager promptly after its receipt of the management fee payable by the Fund pursuant to the Management Agreement.
The fee for the period
from the Effective Date to the end of the quarter during which such sale shall have been commenced shall be pro-rated according to the
proportion which such period bears to the full quarterly period, and upon any termination of this Agreement before the end of any quarter,
the fee for such part of a quarter shall be pro-rated according to the proportion which such period bears to the full quarterly period
and shall be paid promptly after the determination of the Fund's net asset value for the period during which this Agreement is terminated.
If the Manager waives all or a portion of the management fee it is entitled to receive from the Fund, the fee payable to you pursuant
to this Agreement may be reduced as you and the Manager mutually agree.]
[From the New Sub-Advisory
Agreements for the Target Term Fund and Multi-Strategy Fund] [For the purpose of calculating the fee payable to you, the
value of the Fund's total assets shall be computed in the manner and on such days and at such time or times as described in the section
entitled "[Determination of] Net Asset Value" in the Fund's then-current Prospectus and Statement of Additional Information.
You agree to monitor the Fund's assets and to notify the Manager on any day that you determine that a significant event has occurred with
respect to one or more securities held in the Fund's portfolio that would materially affect the value of such securities (provided that
you shall not be responsible for providing information based on valuations provided by third party services which value securities based
upon changes in one or more broad-based indices). At the request of the Manager, the Fund's Valuation Committee or the Board, you agree
to provide additional reasonable assistance to the Manager, the Fund's Valuation Committee, the Board and the Fund's pricing agents in
valuing the Fund's assets, including in connection with fair value pricing of the Fund's assets.]
You will bear all expenses
in connection with the performance of your services under this Agreement. All other expenses to be incurred in the operation of the Fund
(other than those borne by the Manager) will be borne by the Fund, except to the extent specifically assumed by you. The expenses to be
borne by the Fund include, without limitation, the following: [From the New Sub-Advisory Agreement for the Target Term Fund]
[organizational costs, taxes, interest, brokerage fees and commissions, if any, and other expenses in any way related to the execution,
recording and settlement of portfolio security transactions, fees of Trustees who are not the Manager's or your officers, directors or
employees or holders of 5% or more of the outstanding voting securities of you or the Manager or any affiliate of you or the Manager,
Securities and Exchange Commission fees, state Blue Sky qualification fees, advisory fees, shareholder servicing fees, charges of custodians,
transfer and dividend paying agents' fees, certain insurance premiums, industry association fees, outside auditing and legal expenses,
costs of independent pricing services, costs of maintaining corporate existence, expenses of reacquiring shares, expenses in connection
with the Fund's Automatic Dividend Reinvestment Plan, costs of maintaining the required books and accountings (including the costs of
calculating the net asset value of the Fund's shares), costs attributable to investor services (including, without limitation, telephone
and personnel expenses), costs of shareholders' reports and meetings, costs of preparing, printing and mailing share certificates, proxy
statements and prospectuses, and any extraordinary expenses.] [From the New Sub-Advisory Agreements for the Target Term Fund and
Multi-Strategy Fund] [(i) organizational and offering expenses; (ii) taxes
and interest; (iii) brokerage fees and commissions,
if any, and other costs in connection with the purchase or sale of securities and other investment instruments (including, without limitation,
security settlement costs); (iv) loan commitment fees; (v) interest and distributions paid on securities sold short; (vi) fees of Board
members who are not the Manager's or your officers, directors or employees or holders of 5% or more of the outstanding voting securities
of you or the Manager or any affiliate of you or the Manager; (vii) fees and expenses related to the registration and qualification of
the Fund and the Fund's shares for distribution under state and federal securities laws; (viii) fees and expenses related to the registration
and listing the Fund's shares on any securities exchange[, if any]; (ix) expenses related to the Fund's use of leverage, if any; (x) rating
agency fees; (xi) advisory fees; (xii) charges of custodians; (xiii) charges of transfer, dividend disbursing and dividend reinvestment
plan agents; (xiv) certain insurance premiums; (xv) industry association fees; (xvi) outside auditing and legal expenses; (xvii) costs
of independent pricing services; (xviii) costs of maintaining the Fund's existence; (xix) expenses of repurchasing shares; (xx) the Fund's
allocable portion of the costs of the Fund's chief compliance officer and staff; (xxi) costs of preparing, printing and distributing shareholders
reports, notices, press releases, proxy statements, and reports to governmental agencies; (xxii) costs of shareholders' meetings; and
(xxiii) any extraordinary expenses.]
The Manager understands
that in entering into this Agreement you have relied upon the inducements made by the Fund to you under the Management Agreement. The
Manager also understands that you now act, and that from time to time hereafter you may act, as investment adviser or sub-investment adviser
to one or more other investment companies, private funds or other pooled investment vehicles and fiduciary or other managed accounts (collectively,
the "accounts"), and the Manager has no objection to your so acting, provided that when the purchase or sale of securities of
the same issuer is suitable for the investment objectives of two or more accounts managed by you and which have available funds for investment
in the case of a purchase, the available securities will be allocated in a manner believed by you to be equitable to each account. It
is recognized that in some cases this procedure may adversely affect the price paid or received by the Fund or the size of the position
obtainable for or disposed of by the Fund.
In addition, it is understood
that the persons employed by you to assist in the performance of your duties hereunder will not devote their full time to such services
and nothing contained herein shall be deemed to limit or restrict your right or the right of any of your affiliates to engage in and devote
time and attention to other businesses or to render services of whatever kind or nature.
You shall exercise your
best judgment in rendering the services to be provided hereunder, and the Manager agrees as an inducement to your undertaking the same
that you shall not be liable hereunder for any error of judgment or mistake of law or for any loss suffered by the Fund or the Manager,
provided that nothing herein shall be deemed to protect or purport to protect you against any liability to the Manager, the Fund or the
Fund's shareholders to which you would otherwise be subject by reason of willful misfeasance, bad faith or gross negligence in the performance
of your duties hereunder, or by reason of your reckless disregard of your obligations and duties hereunder. In no event will you have
any responsibility for the acts or omissions of the Manager.
Except
as may otherwise be provided by the Investment Company Act or any other federal securities law or the Commodity Exchange Act (the
"CEA"), neither you nor any of your directors, officers, members or employees ("Sub-Adviser Affiliates") shall be
liable for any losses, claims, damages, liabilities or litigation (including legal and other expenses) ("Losses") incurred or
suffered by the Manager or the
Fund as a result of any act or
omission by you or the Sub-Adviser Affiliates with respect to the Fund, except that nothing
in this Agreement shall operate or purport to operate in any way to exculpate, waive or limit the liability of you or the Sub-Adviser
Affiliates for, and you shall indemnify and hold harmless the Manager and the Fund, and all affiliated persons (within the meaning of
Section 2(a)(3) of the Investment Company Act) thereof and all controlling persons (as described in Section 15 of the Securities Act of
1933, as amended (the "Securities Act")) (collectively, "Manager Indemnitees") thereof against, any and all Losses
to which any of the Manager Indemnitees may become subject under the Investment Company Act, the Investment Advisers
Act, the CEA or the Securities Act, or under any other statute, at common law or otherwise arising out of or based on (i) your willful
misfeasance, bad faith, reckless disregard or gross negligence, and/or (ii) any untrue statement of a material fact contained in the Prospectus,
[Statement of Additional Information,] proxy materials, reports, advertisements, sales literature, or other materials pertaining to the
Fund or the omission to state therein a material fact known to you that was required to be stated therein or necessary to make the statements
therein not misleading, if such statement or omission was made in reliance upon information furnished to the Manager Indemnitees by the
Sub-Adviser Indemnitees (as defined below) for use therein.
Except
as may otherwise be provided by the Investment Company Act or any other federal securities law or the CEA, neither the Manager, the Fund
nor any of their directors, officers, members or employees ("Manager Affiliates") shall be liable for any Losses incurred or
suffered by you as a result of any act or omission of the Manager or the Manager Affiliates with respect to the Fund, except that nothing
in this Agreement shall operate or purport to operate in any way to exculpate, waive or limit the liability of the Manager for, and the
Manager shall indemnify and hold harmless you, all of your affiliated persons (within the meaning of Section 2(a)(3) of the Investment
Company Act) and all of your controlling persons (as described in Section 15 of the Securities Act) (collectively, "Sub-Adviser
Indemnitees") against, any and all Losses to which any of the Sub-Adviser Indemnitees may become subject under the Investment Company
Act, the Investment Advisers Act, the CEA or the Securities Act, or under any other statute, at common law or otherwise arising out of
or based on (i) the Manager's willful misfeasance, bad faith, reckless disregard or gross negligence, (ii) any untrue statement of a material
fact contained in the Prospectus, [Statement of Additional Information,] proxy materials, reports, advertisements, sales literature, or
other materials pertaining to the Fund or the omission to state therein a material fact known to the Manager that was required to be stated
therein or necessary to make the statements therein not misleading, unless such statement or omission was made in reliance upon information
furnished to the Manager Indemnitees by the Sub-Adviser Indemnitees for use therein, and/or (iii) any Losses accruing to the extent, if
any, caused by or based upon the conduct of any other sub-adviser to the Fund.
Promptly
after receipt of notice of any action, arbitration, claim, demand, dispute, investigation, lawsuit or other proceeding (each, a "Proceeding")
by a party seeking to be indemnified hereunder (the "Indemnified Party"), the Indemnified Party will, if a claim in respect
thereof is to be made against a party against whom indemnification is sought hereunder (the "Indemnifying Party"), notify the
Indemnifying Party in writing of the commencement of such Proceeding; provided that, the failure to so notify the Indemnifying Party in
the absence of a showing of actual prejudice shall not relieve the Indemnifying Party from any indemnification liability which it may
have to the Indemnified Party. The Indemnifying Party shall be entitled to participate in, and, to
the extent that it may wish, assume the defense thereof (in its own name or in the name and on behalf of any Indemnified Party, or both,
with counsel reasonably satisfactory to such Indemnified Party) by giving written notice to the Indemnified Party within 10 days
of receiving notice of the Proceeding (or such shorter period as is required to respond to the Proceeding); provided,
however,
if the defendants in any such action
include (or will include) both the Indemnified Party and an Indemnifying Party and the Indemnified Party shall have reasonably concluded
that there may be a conflict between the positions of the Indemnified Party and an Indemnifying Party in conducting the defense of any
such action or that there may be legal defenses available to it which are inconsistent with those available to an Indemnifying Party,
the Indemnified Party shall have the right to select one separate counsel (in addition to local counsel) to assume such legal defense
and to otherwise participate in the defense of such action on behalf of such Indemnified Party at such Indemnified Party's sole expense.
Upon receipt of notice from an Indemnifying Party to such Indemnified Party of its election so to assume the defense of such action and
approval by the Indemnified Party of counsel, which approval shall not be unreasonably withheld (and any disapproval shall be accompanied
by a written statement of the reasons therefor), the Indemnifying Party will not be liable to such Indemnified Party hereunder for any
legal or other expenses subsequently incurred by such Indemnified Party in connection with the defense thereof. No Indemnifying Party
shall be liable under this Agreement for any settlement of any Proceeding entered into without its consent with respect to which indemnity
may be sought hereunder, nor shall any Indemnifying Party enter into any settlement (other than a purely monetary "no admission"
settlement) without the consent of the Indemnified Party.
You may delegate some of
your duties under this Agreement to one or more of your affiliates; provided, however, that (i) you shall provide prior notice to the
Manager of any such delegation and the Manager consents to such delegation, (ii) any delegation of investment advisory duties within the
definition of "investment adviser" under the Investment Company Act is subject to and conditioned on the approval of the Fund's
Board and/or the Fund's shareholders as may be required pursuant to Section 15 of the Investment Company Act, (iii) you at all times shall
supervise and oversee the performance of any such services delegated by you to your affiliate, (iv) no additional charges, fees or other
compensation shall be paid by the Manager or the Fund for any such services delegated by you to your affiliate, and (v) you at all times
shall remain liable to the Manager and the Fund for your obligations under this Agreement regardless of whether services hereunder are
provided by you or any of your affiliates.
This Agreement shall continue
until April 4, 2023, and thereafter shall continue automatically for successive annual periods ending on April 4th of each
year, provided such continuance is specifically approved at least annually by (i) the Fund's Board or (ii) vote of a majority (as defined
in the Investment Company Act) of the Fund's outstanding voting securities, provided that in either event its continuance also is approved
by a majority of the Fund's Board members who are not "interested persons" (as defined in the Investment Company Act) of the
Fund or any party to this Agreement, by vote cast in person at a meeting called for the purpose of voting on such approval. This Agreement
is terminable without penalty (i) by the Manager on not more than 60 days' notice to you, (ii) by the Fund's Board or by vote of the holders
of a majority of the Fund's outstanding voting securities on not more than 60 days' notice to you, or (iii) by you on not less than 90
days' notice to the Fund and the Manager. This Agreement also will terminate automatically in the event of its assignment (as defined
in the Investment Company Act or the Investment Advisers Act) and you shall be notified by the Fund and the Manager, or you shall notify
the Fund and the Manager, as applicable, as soon as reasonably practicable and as permissible under applicable law or agreement. In addition,
notwithstanding anything herein to the contrary, if the Management Agreement terminates for any reason, this Agreement shall terminate
effective upon the date the Management Agreement terminates.
The Manager acknowledges
that it has received and has had an opportunity to read a copy of your Form ADV Part 2A (the "Brochure") and a copy of the Form
ADV Part 2B with respect to your personnel
with the most significant responsibility for
providing advisory services to the Fund (the "Brochure Supplement"). The Manager agrees that the Brochure and Brochure Supplement,
as well as other client communications, may be transmitted to the Manager electronically.
The
Manager represents and warrants to you that (a) the retention of you by the Manager as contemplated by this Agreement is authorized by
the governing documents of the Manager; (b) the execution, delivery and performance of this Agreement do not violate any obligation by
which the Manager or its property is bound, whether arising by contract, operation of law or otherwise; (c) this Agreement has been duly
approved by the Fund's Board in accordance with all applicable requirements of the Investment Company Act;
and (d) this Agreement has been duly authorized by appropriate action of the Manager and when executed and delivered by the Manager will
be a legal, valid and binding obligation of the Manager, enforceable against the Manager in accordance with its terms.
You
represent and warrant to the Manager that (a) your acceptance of the Manager's retention of you to serve as a sub-adviser of the Fund
as contemplated by this Agreement is authorized by your governing documents; (b) the execution, delivery and performance of this Agreement
do not violate any obligation by which you or your property is bound, whether arising by contract, operation of law or otherwise; and
(c) this Agreement has been duly authorized by appropriate action and when executed and delivered by you will be a legal, valid and binding
obligation, enforceable against you in accordance with its terms.
The Fund has claimed an
exclusion from the definition of a Commodity Pool Operator pursuant to CFTC Rule 4.5 (the "CPO Exclusion") and you shall not
manage the Fund's assets in a manner that would cause the Fund to not qualify for the CPO Exclusion until otherwise indicated. In the
event that the Fund no longer relies on the CPO Exclusion and you intend to rely on CFTC Rule 4.7, unless advised by the Manager to the
contrary, the Manager represents that the Fund is a "qualified eligible person" under the rule, consents to the Fund being treated
as an exempt account under the rule, and acknowledges the legend set forth above its signature below. In
addition, the Manager represents to you that it is registered as a Commodity Pool Operator and is a member of the National Futures Association
in such capacity, to the extent required by the nature of its activities, and you represent to the Manager that you are registered as
a Commodity Trading Advisor and are a member of the National Futures Association in such capacity or are exempt from such membership.
No party to this Agreement
will disclose or use any records or information obtained pursuant to this Agreement in any manner whatsoever, except as expressly authorized
in this Agreement or, with respect to you, as may reasonably be required to execute transactions on behalf of the Fund or, with respect
to the Manager, as may reasonably be required to provide its services to the Fund. The parties will keep confidential any non-public information
obtained directly as a result of this service relationship; provided that the Manager may make any disclosure to its affiliates, the Fund,
or the Fund's Board, legal counsel or auditors or other service providers to the Fund, as the Manager may reasonably determine necessary
in its sole discretion; provided that no such information may be used for any trading or investment purposes unrelated to management of
the Fund. Notwithstanding the foregoing, any party may disclose such non-public information if (a) such information is or hereafter otherwise
is known by the receiving party or has been disclosed, directly or indirectly, to others or becomes ascertainable from public or published
information or trade sources, (b) if such disclosure is required by applicable federal, state or other law or regulation, (c) if such
disclosure is required or requested by regulatory authorities or judicial process, (d)
such disclosure is reasonably required by legal
counsel or auditors of the party (or of the Fund, the Fund's Board or affiliates of the Manager) in connection with the performance of
their professional services, or (e) as may otherwise be contemplated by this Agreement. You shall not disclose information regarding characteristics
of the Fund's assets, trading history, portfolio holdings, performance information or any other related information to any third party,
except in compliance with the Fund's policies on disclosure of portfolio holdings or as required by applicable law or regulation.
No provision of this Agreement
may be changed, waived or discharged unless signed in writing by the parties hereto. This Agreement shall be governed by the laws of the
State of New York, without regard to the conflict of law principles thereof, provided that nothing herein shall be construed in a manner
inconsistent with the Investment Company Act or the Investment Advisers Act. This Agreement may be executed in several counterparts, each
of which shall be deemed an original for all purposes, including judicial proof of the terms hereof, and all of which together shall constitute
and be deemed one and the same agreement. Nothing in this Agreement shall be deemed a limitation or waiver of any obligation or duty that
may not by law be limited or waived. If any one or more of the provisions of this Agreement shall be held contrary to express law or against
public policy, or shall for any reason whatsoever be held invalid, then such provisions shall be deemed severable from the remainder of
this Agreement and shall in no way affect the validity or enforceability of the other provisions of this Agreement. The rights of indemnification
herein shall not be exclusive of or affect any other rights to which any person may be entitled by contract or otherwise by law and shall
survive termination of this Agreement.
Unless otherwise provided
herein or agreed to in writing by the parties, all notices or instructions permitted or required under this Agreement shall be deemed
to have been properly given if sent by regular first-class mail, registered mail, private courier, facsimile or electronically and addressed
to (or delivered to) the respective party at the address set forth above or at such other address or addresses as shall be specified,
in each case, in a notice similarly given. Each party may rely upon any notice from the other party or other communication reasonably
believed by the receiving party to be genuine.
The Fund is expressly made
a third party beneficiary of this Agreement with rights to the same extent as if it had been a party hereto.
This Agreement contains
all of the terms agreed upon or made by the parties relating to the subject matter of this Agreement, and supersedes all prior and contemporaneous
agreements, negotiations, correspondence, undertakings and communications of the parties, oral or written, respecting such subject matter.
PURSUANT TO AN EXEMPTION
FROM THE COMMODITY FUTURES TRADING COMMISSION IN CONNECTION WITH ACCOUNTS OF QUALIFIED ELIGIBLE PERSONS, THIS BROCHURE OR ACCOUNT DOCUMENT
IS NOT REQUIRED TO BE, AND HAS NOT BEEN, FILED WITH THE COMMISSION. THE COMMODITY FUTURES TRADING COMMISSION DOES NOT PASS UPON THE MERITS
OF PARTICIPATING IN A TRADING PROGRAM OR UPON THE ADEQUACY OR ACCURACY OF COMMODITY TRADING ADVISOR DISCLOSURE. CONSEQUENTLY, THE COMMODITY
FUTURES TRADING COMMISSION HAS NOT REVIEWED OR APPROVED THIS TRADING PROGRAM OR THIS BROCHURE OR ACCOUNT DOCUMENT.
If the foregoing is in
accordance with your understanding, will you kindly so indicate by signing and returning to us the enclosed copy hereof.
|
Very truly yours, |
|
|
|
BNY MELLON INVESTMENT ADVISER, INC. |
|
|
|
By: _________________________
Name:
Title:
|
Accepted: |
|
|
|
Alcentra NY, LLC |
|
|
|
By: ______________________
Name:
Title: |
|
Important
Notice Regarding the Availability of Proxy Materials for the Special Joint Meeting of Shareholders to be Held on October 13, 2022:
The Letter to Shareholders, Notice of Special Joint Meeting of Shareholders and Joint Proxy Statement are available at https://im.bnymellon.com/us/en/individual/resources/proxy-materials.jsp.
BNY MELLON HIGH YIELD
STRATEGIES FUND
The undersigned shareholder
of BNY Mellon High Yield Strategies Fund (the "Fund"), hereby appoints Jeff Prusnofsky and James Bitetto, and each of them,
the attorneys and proxies of the undersigned, with full power of substitution, to vote, as indicated herein, all of the shares of beneficial
interest of the Fund standing in the name of the undersigned at the close of business on August 16, 2022, at a Special Joint Meeting of
Shareholders to be held over the Internet in a virtual meeting format only at 10:00 a.m., Eastern time, on Thursday, October 13, 2022,
and at any and all postponements or adjournments thereof, with all of the powers the undersigned would possess if then and there personally
present and especially (but without limiting the general authorization and power hereby given) to vote as indicated on the proposal, as
more fully described in the Joint Proxy Statement for the meeting.
The meeting will be conducted exclusively online
via live webcast. Shareholders may request the meeting credentials by emailing attendameeting@astfinancial.com. Please include your full
name, address, your control number found on this enclosed proxy card, your intent to attend the virtual meeting and "BNY Mellon High
Yield Strategies Fund" in the subject line. The meeting will begin promptly at 10:00 a.m., Eastern time. The Fund encourages you
to access the meeting a few minutes prior to the start time leaving ample time for the check in. Only shareholders of the Fund will be
able to participate in the meeting. You may vote during the meeting by following the instructions available on the meeting website. If
you have any questions before you vote, please call the Fund's proxy solicitor, AST Fund Solutions, LLC, at (866) 796-7181.
THIS PROXY IS SOLICITED BY THE FUND'S
BOARD OF TRUSTEES AND WILL BE VOTED "FOR" THE PROPOSAL SHOWN ON THE REVERSE SIDE UNLESS OTHERWISE INDICATED.
PLEASE SIGN AND DATE ON THE REVERSE SIDE
PROXY
TABULATOR
P.O. BOX 9112
FARMINGDALE, NY 11735
SCAN TO
View Materials & Vote >
THREE EASY WAYS TO VOTE YOUR PROXY
To vote over the Internet
1) Read the Joint Proxy Statement and have the proxy card below at hand.
2) Go to website www.proxyvote.com or scan the QR Barcode above.
3) Follow the instructions provided on the website.
To vote by Telephone
1) Read the Joint Proxy Statement and have the proxy card below at hand.
2) Call 1-800-690-6903.
3) Follow the instructions.
To vote by Mail
1) Read the Joint Proxy Statement.
2) Check the appropriate box on the proxy card below.
3) Sign and date the proxy card.
4) Return the proxy card in the enclosed postage-paid envelope provided.
If you are NOT voting by Telephone or over the Internet, Please
Sign, Date and Return the Proxy Card
Promptly Using the Enclosed Envelope.
You may also vote at the meeting. Any shareholder who attends
the meeting virtually may vote during the meeting by following the instructions available on the meeting website.
TO VOTE, MARK A BLOCK BELOW IN BLUE OR BLACK INK AS
FOLLOWS: X
---------------------------------------------------------------------------------------------------------------------
The Fund's Board of Trustees recommends you vote
FOR the following proposal.
BNY MELLON HIGH YIELD
STRATEGIES FUND
1. |
To approve a sub-investment advisory agreement between BNY Mellon Investment Adviser, Inc., on behalf of the Fund, and Alcentra NY, LLC. |
|
|
FOR |
AGAINST |
ABSTAIN |
¨ |
¨ |
¨ |
2. |
In their discretion,
the proxies are authorized to vote upon such other business as may properly come before the meeting and any postponement or adjournment
thereof, as described in the Joint Proxy Statement. |
Sign, Date and Return the Proxy Card Promptly Using
the Enclosed Envelope
Signature(s) should be exactly as name or names
appearing on this proxy. If shares are held jointly, each holder should sign. If signing is by attorney, executor, administrator, trustee
or guardian, please give full
title. By signing this proxy card, receipt of
the accompanying Notice of Special Joint Meeting of Shareholders and Joint Proxy Statement is acknowledged.
___________________________________
Signature (Please Sign Within Box) |
______
Date |
_______________________
Signature (Joint Owners) |
_______
Date |
Important
Notice Regarding the Availability of Proxy Materials for the Special Joint Meeting of Shareholders to be Held on October 13, 2022:
The Letter to Shareholders, Notice of Special Joint Meeting of Shareholders and Joint Proxy Statement are available at https://im.bnymellon.com/us/en/individual/resources/proxy-materials.jsp.
BNY Mellon ALCENTRA
GLOBAL CREDIT INCOME 2024 TARGET TERM Fund, INC.
The undersigned shareholder
of BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. (the "Fund"), hereby appoints Jeff Prusnofsky and James
Bitetto, and each of them, the attorneys and proxies of the undersigned, with full power of substitution, to vote, as indicated herein,
all of the shares of common stock of the Fund standing in the name of the undersigned at the close of business on August 16, 2022, at
a Special Joint Meeting of Shareholders to be held over the Internet in a virtual meeting format only at 10:00 a.m., Eastern time, on
Thursday, October 13, 2022, and at any and all postponements or adjournments thereof, with all of the powers the undersigned would possess
if then and there personally present and especially (but without limiting the general authorization and power hereby given) to vote as
indicated on the proposal, as more fully described in the Joint Proxy Statement for the meeting.
The meeting will be conducted exclusively online
via live webcast. Shareholders may request the meeting credentials by emailing attendameeting@astfinancial.com. Please include your full
name, address, your control number found on this enclosed proxy card, your intent to attend the virtual meeting and "BNY Mellon Alcentra
Global Credit Income 2024 Target Term Fund, Inc." in the subject line. The meeting will begin promptly at 10:00 a.m., Eastern time.
The Fund encourages you to access the meeting a few minutes prior to the start time leaving ample time for the check in. Only shareholders
of the Fund will be able to participate in the meeting. You may vote during the meeting by following the instructions available on the
meeting website. If you have any questions before you vote, please call the Fund's proxy solicitor, AST Fund Solutions, LLC, at (866)
796-7181.
THIS PROXY IS SOLICITED BY THE FUND'S
BOARD OF DIRECTORS AND WILL BE VOTED "FOR" THE PROPOSAL SHOWN ON THE REVERSE SIDE UNLESS OTHERWISE INDICATED.
PLEASE SIGN AND DATE ON THE REVERSE SIDE
PROXY
TABULATOR
P.O. BOX 9112
FARMINGDALE, NY 11735
SCAN TO
View Materials & Vote >
THREE EASY WAYS TO VOTE YOUR PROXY
To vote over the Internet
1) Read the Joint Proxy Statement and have the proxy card below at hand.
2) Go to website www.proxyvote.com or scan the QR Barcode above.
3) Follow the instructions provided on the website.
To vote by Telephone
1) Read the Joint Proxy Statement and have the proxy card below at hand.
2) Call 1-800-690-6903.
3) Follow the instructions.
To vote by Mail
1) Read the Joint Proxy Statement.
2) Check the appropriate box on the proxy card below.
3) Sign and date the proxy card.
4) Return the proxy card in the enclosed postage-paid envelope provided.
If you are NOT voting by Telephone or over the Internet, Please
Sign, Date and Return the Proxy Card
Promptly Using the Enclosed Envelope.
You may also vote at the meeting. Any shareholder who attends
the meeting virtually may vote during the meeting by following the instructions available on the meeting website.
TO VOTE, MARK A BLOCK BELOW IN BLUE OR BLACK INK AS
FOLLOWS: X
---------------------------------------------------------------------------------------------------------------------
The Fund's Board of Directors recommends you
vote FOR the following proposal.
BNY Mellon ALCENTRA
GLOBAL CREDIT INCOME 2024 TARGET TERM Fund, INC.
1. |
To approve a sub-investment advisory agreement between BNY Mellon Investment Adviser, Inc., on behalf of the Fund, and Alcentra NY, LLC. |
FOR |
AGAINST |
ABSTAIN |
¨ |
¨ |
¨ |
|
2. In their discretion,
the proxies are authorized to vote upon such other business as may properly come before the meeting and any postponement or adjournment
thereof, as described in the Joint Proxy Statement. |
Sign, Date and Return the Proxy Card Promptly Using
the Enclosed Envelope
Signature(s) should be exactly as name or names
appearing on this proxy. If shares are held jointly, each holder should sign. If signing is by attorney, executor, administrator, trustee
or guardian, please give full
title. By signing this proxy card, receipt of
the accompanying Notice of Special Joint Meeting of Shareholders and Joint Proxy Statement is acknowledged.
___________________________________
Signature (Please Sign Within Box) |
______
Date |
_______________________
Signature (Joint Owners) |
_______
Date |
Important
Notice Regarding the Availability of Proxy Materials for the Special Joint Meeting of Shareholders to be Held on October 13, 2022:
The Letter to Shareholders, Notice of Special Joint Meeting of Shareholders and Joint Proxy Statement are available at https://im.bnymellon.com/us/en/individual/resources/proxy-materials.jsp.
BNY Mellon ALCENTRA
GLOBAL MULTI-STRATEGY CREDIT FUND, INC.
The undersigned shareholder
of BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. (the "Fund"), hereby appoints Jeff Prusnofsky and James Bitetto,
and each of them, the attorneys and proxies of the undersigned, with full power of substitution, to vote, as indicated herein, all of
the shares of common stock of the Fund standing in the name of the undersigned at the close of business on August 16, 2022, at a Special
Joint Meeting of Shareholders to be held over the Internet in a virtual meeting format only at 10:00 a.m., Eastern time, on Thursday,
October 13, 2022, and at any and all postponements or adjournments thereof, with all of the powers the undersigned would possess if then
and there personally present and especially (but without limiting the general authorization and power hereby given) to vote as indicated
on the proposal, as more fully described in the Joint Proxy Statement for the meeting.
The meeting will be conducted exclusively online
via live webcast. Shareholders may request the meeting credentials by emailing attendameeting@astfinancial.com. Please include your full
name, address, your control number found on this enclosed proxy card, your intent to attend the virtual meeting and "BNY Mellon Alcentra
Global Multi-Strategy Credit Fund, Inc." in the subject line. The meeting will begin promptly at 10:00 a.m., Eastern time. The Fund
encourages you to access the meeting a few minutes prior to the start time leaving ample time for the check in. Only shareholders of the
Fund will be able to participate in the meeting. You may vote during the meeting by following the instructions available on the meeting
website. If you have any questions before you vote, please call the Fund's proxy solicitor, AST Fund Solutions, LLC, at (866) 796-7181.
THIS PROXY IS SOLICITED BY THE FUND'S
BOARD OF DIRECTORS AND WILL BE VOTED "FOR" THE PROPOSAL SHOWN ON THE REVERSE SIDE UNLESS OTHERWISE INDICATED.
PLEASE SIGN AND DATE ON THE REVERSE SIDE
PROXY
TABULATOR
P.O. BOX 9112
FARMINGDALE, NY 11735
SCAN TO
View Materials & Vote >
THREE EASY WAYS TO VOTE YOUR PROXY
To vote over the Internet
1) Read the Joint Proxy Statement and have the proxy card below at hand.
2) Go to website www.proxyvote.com or scan the QR Barcode above.
3) Follow the instructions provided on the website.
To vote by Telephone
1) Read the Joint Proxy Statement and have the proxy card below at hand.
2) Call 1-800-690-6903.
3) Follow the instructions.
To vote by Mail
1) Read the Joint Proxy Statement.
2) Check the appropriate box on the proxy card below.
3) Sign and date the proxy card.
4) Return the proxy card in the enclosed postage-paid envelope provided.
If you are NOT voting by Telephone or over the Internet, Please
Sign, Date and Return the Proxy Card
Promptly Using the Enclosed Envelope.
You may also vote at the meeting. Any shareholder who attends
the meeting virtually may vote during the meeting by following the instructions available on the meeting website.
TO VOTE, MARK A BLOCK BELOW IN BLUE OR BLACK INK AS
FOLLOWS: X
---------------------------------------------------------------------------------------------------------------------
The Fund's Board of Directors recommends you
vote FOR the following proposal.
BNY Mellon ALCENTRA
GLOBAL MULTI-STRATEGY CREDIT FUND, INC.
1. |
To approve a sub-investment advisory agreement between BNY Mellon Investment Adviser, Inc., on behalf of the Fund, and Alcentra NY, LLC. |
FOR |
AGAINST |
ABSTAIN |
¨ |
¨ |
¨ |
2. |
In their discretion,
the proxies are authorized to vote upon such other business as may properly come before the meeting and any postponement or adjournment
thereof, as described in the Joint Proxy Statement. |
Sign, Date and Return the Proxy Card Promptly Using
the Enclosed Envelope
Signature(s) should be exactly as name or names
appearing on this proxy. If shares are held jointly, each holder should sign. If signing is by attorney, executor, administrator, trustee
or guardian, please give full
title. By signing this proxy card, receipt of
the accompanying Notice of Special Joint Meeting of Shareholders and Joint Proxy Statement is acknowledged.
___________________________________
Signature (Please Sign Within Box) |
______
Date |
_______________________
Signature (Joint Owners) |
_______
Date |
BNY Mellon Alcentra Gl C... (NYSE:DCF)
Historical Stock Chart
From Sep 2024 to Oct 2024
BNY Mellon Alcentra Gl C... (NYSE:DCF)
Historical Stock Chart
From Oct 2023 to Oct 2024